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PDAC is a pancreatic epithelial malignancy and demonstrates aggressive
progression and bleak patient prognosis. Despite decades of research, the
evolution of novel diagnostics and intervention modalities for PDAC is stagnant.
This dissertation explores the characteristic aberrant and elevated expression of
mucins in PDAC. Beginning with the hypothesis that mucins are associated with
disease aggressiveness, analysis of PDAC patient survival in TCGA revealed no
associations between single mucin expression and patient survival. This led to the
underlying issue of PDAC tumor cellularity since this disease demonstrates
variability in the proportion of cancer cells within the tumor. Tumor purity assessed
with the ABSOLUTE computational algorithm is reported for all patient samples in
the TCGA PDAC dataset. Using these purity scores, a mathematical correction of
epithelial-specific mucin expression was devised. Again, no significant association
between PDAC patient survival and mucin expression was found. Therefore, I
investigated combinatorial expression of mucins by Spearman’s nonparametric
PCA, which resulted in four groups of mutual expression: Group One=
MUC7/12/17, Group Two= MUC1/3/13/19/20, Group Three= MUC6/15/22, and
Group Four= MUC2/4/5AC/5B/16/21. These four groups were associated
significantly with survival outcomes. To determine the biological implications of
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these four groups, PCA scores for all patients were correlated to whole
transcriptomes. Significantly correlated genes were assessed for biological
pathway upregulation. The four pathway composites revealed potential
pathological signatures unrelated to previous PDAC classifications, representing
novel PDAC subtypes. The role of mucin splice variants (SVs) was assessed and
correlated to PDAC patient survival. Bioinformatic studies revealed 12 total mucin
SVs significantly associated with survival. Better survival was correlated with
expression of four MUC1, one MUC13, and one MUC20 SVs. High expression of
two MUC4, one MUC15, one MUC16, one MUC21, and one MUC22 SVs were
correlated with worse survival. The correlation between MUC4-sv-215 and
MUC13-sv-201 SVs and survival were PCR validated in PDAC patient samples.
These MUC4Δ6 prognostic findings contributed to in vitro studies and the
development of a novel nanoparticle assay that detects MUC4-sv-215 in patient
biofluids. The cumulative impact of the results described here may advance the
clinical utility of mucins and associated SVs for improved diagnosis of PDAC.
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CHAPTER 1:
INTRODUCTION
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The pancreas is the largest glandular organ in the human body, and its
functions and development are intriguingly complex. Unique among all human
glands, the pancreas has both endocrine and exocrine secretions and provides
vital roles in digestion and homeostasis. While much has been discovered about
the physical course of pancreatic embryology, the specific molecular signaling
pathways involved in the regulation of its tissue differentiation have proven to be
more elusive and shrouded in convolution.
Furthermore, disorders and diseases of the pancreas present with lifealtering consequences and their respective treatments, albeit often failing to lead
to cures in patients, range from long-term maintenance to short-term, palliative
intervention. Also, medical treatment of the pancreas bridges many different
specialties from endocrinology, to gastrointestinal, to immunology, and at times
surgery, with each frequently having opposing approaches to therapy.
I begin with an overview of the anatomy of the pancreas and explore the
development of the human pancreas starting at the first collections of cells at the
26th day of embryonic development and follow it through the multilayers of the cell
and inter-organ tissue signaling. I will then proceed into three of the most common
diseases of the pancreas and attempt to explore what contributes to the complexity
of their establishment and treatments.
1.A Pancreatic Anatomy
Retroperitoneally and transversely along the posterior abdominal wall,
posterior to the stomach, in the left upper abdomen, the pancreas is a large organ
utilizing considerable space. Structurally, the pancreas is comprised of three main
21
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Figure 1.1: Pancreatic Anatomy

The pancreas runs midline-left, laterally across the upper abdomen inferior to the
liver and diaphragm and posterior to the stomach.

Used with permission, © Terese Winslow, 2009. (Appendix A-1)
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FIGURE 1.1: PANCREATIC ANATOMY
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sections: the head, which is posterior and dextrolateral to the stomach, the body,
oriented mediodorsal to the stomach, and the tail, situated sinistrolateral to the
stomach and ventral to the left kidney. (Fig 1.1) Inferior to the liver, the head of the
pancreas receives the common bile duct superiorly and presents the anastomosed
bile duct and pancreatic duct to the duodenal lumen via the major duodenal papilla
of Vater under smooth muscular control of the sphincter of hepatopancreatic
ampulla. In most people, the vestigial proximal portion of the dorsal pre-pancreatic
bud, known as the accessory pancreatic duct of Santorini, remains intact and fuses
to the duodenum superior to the major papilla.
The major functions of the pancreas can be divided into two aspects (Fig
1.2). The digestive roles are performed by exocrine cells composed of acinar cells,
which produce and secrete enzymes, and ductal cells, which conduct those
enzymes from the acini to the central pancreatic duct then to the duodenal lumen
where they mix with chyme. The hormonal functions are conducted by clusters of
endocrine cells arranged in cords juxtaposed to acini and ducts known as islets of
Langerhans. Pancreatic islets are composed of glucagon-producing α-cells,
insulin-producing β-cells, pancreatic polypeptide-producing γ-cells, somatostatinproducing δ-cells, and ghrelin-producing ε-cells (Fig 1.3). Together, the endocrine
population comprises about 2% of the total mass of the pancreas whereas the
exocrine population makes up the remaining 98%. The establishment of these two
very distinct populations of cells from a common progenitor origin is complex,
requiring many cooperative and competitive signaling cascades.

24

Figure 1.2: Endocrine and Exocrine Cells of the Pancreas
The human pancreas is located left shifted across the midline in the upper
abdomen and is comprised of endocrine and exocrine cell populations, giving the
pancreas dual biological functions.

Used with Permission, cancer.org (Appendix A-2)1
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FIGURE 1.2: ENDOCRINE AND EXOCRINE CELLS OF THE PANCREAS
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Figure 1.3: Histological Architecture of the Pancreas

The functional histology is comprised of exocrine cells retained in acini secreting
digestive products into ductal lumen and clusters of endocrine cells releasing their
hormonal and peptidyl products into vascular circulation.

Used with permission from ‘Exocrine Pancreas’ by Ed Friedlander MD, Department of Pathology,
Kansas City University, Kansas City, MO (Appendix A-3)2
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FIGURE 1.3: HISTOLOGICAL ARCHITECTURE OF THE PANCREAS
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1.B Pancreatic Budding and Fusion
In the first trimester of embryonic development, 26 days after gestation, a
small cluster of cells can be observed on the posterior aspect of the gut tube,
juxtaposed to the duodenal anlage distal to the stomach, yielding the first evidence
of pancreatic development.3 Following the expansion of these cells and preceding
loss of contact between the gut tube and notochord due to the fusion of the two
dorsal aortas4, the endoderm invades the overlaying mesoderm. These initial
differentiation regulatory signals have been suggested to come from the
notochord-derived morphogens via sonic hedgehog (Shh) inhibition in the
pancreatic precursor cells. The absence of Shh in the pancreas stands in stark
contrast to the rest of the gastrointestinal system where it remains an essential
pathway to organogenesis. Six days following this event, a second bud arises from
the caudal hepatic bud representing the ventral pancreatic bud. Shortly before the
presentation of the ventral pancreatic bud, the epithelium of the coelom rapidly
divides and sequesters the gut and pancreas from the aorta and non-gut tissues
while mesenchyme simultaneously proliferates and begins to separate the
pancreatic and coelomic epithelium.4 The epithelium of both pancreatic ducts
begins to proliferate and elongate in a stalk-like manner with branching points
arising at acute angles in a fashion that omits intervening mesenchyme between
branches.5 Thus, this morphological development results in a tissue comprised of
yet an indistinguishable cell population with no distinctive subcellular structures.
Between embryonic day 37 and 42, the gut tube experiences a posterio-anterior
loop elongation and physiological hernia into the umbilicus followed by clockwise
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rotation in which the pylorus shifts dextrolateral as the duodenum twists
establishing its final C-loop. As a consequence of this rotation, the ventral and
dorsal pancreatic buds come into contact, and the fusion of the buds and their
ducts ensue.
1.C Pancreatic Progenitor Cell Differentiation
To this point, all pancreatic endocrine cells have appeared primarily
glucagon positive. However, following the initiation of gut rotation, the pancreas
enters a phase known as the “secondary transition” in which endocrine cell
populations increase in dramatic fashion and shift toward insulin-secreting β-cells6
and enzyme granules appear in dense concentration in newly differentiated acinar
cells distinguishable from ductal cells by their expression of pancreatic specific
transcription factor 1α (PTF1α).7 Distal epithelial cells begin expressing PTF1a
around E12 and subsequently form a spherical lumen. Initiating between E14 and
E15, these PTF1a-positive cells increase in size, shift their nuclei to the basal
aspect, and demonstrate eosinophilic cytoplasm as digestive secretions are
increasingly upregulated.8 Specifically in insulin-positive endocrine cells, formation
of cords of endocrine-positive cells begins as the cells down-regulate adhesion
molecules, shift their plane of proliferation by 90 degrees, and begin migrating
away from the basement membrane of the epithelial proto-lumen.4 It has been
suggested that this transition is also marked by a reduction in pancreatic duodenal
box-1 (Pdx1) expression which has been present in the developing pancreatic cells
since the generation of the pre-pancreatic buds in a process likely analogous to
epithelial-to-mesenchymal transition.9, 10 However, Gannon and colleagues used
30

a Pdx1-knockout mouse model and demonstrated that the mice failed to establish
entire populations of endocrine-positive islets.11
1.D Mesenchymal Signaling
Early studies of the differentiation of the pancreatic epithelium into
endocrine islets and exocrine acini revealed the presence and selective contact of
pancreatic mesenchyme to pancreatic epithelia. In the complete absence of
mesenchyme, pancreatic epithelium collectively differentiated to endocrine islets.12
When mesenchyme was present and contacting pancreatic epithelium, acinar
differentiation dominated.13 The mediator of this effect was discovered to be the
induction of Notch, enhancement of downstream hairy enhancer of split-1 (Hes1),
and consequential neurogenic-3 (Ngn3) inhibition.14 Given the lack of co-localized
expression of E-cadherin and Ngn315, procession toward terminal pancreatic
differentiation is likely due to an initial, temporal inhibition of islet development
following inhibitory signaling of Ngn3 and enhanced Hes1 in the endocrinenegative epithelium. More illuminating, Shih and group demonstrated that the
differentiation signaling might be dose-dependent, in which high Notch was able
to activate Hes1 and SRY-Box Transcription Factor 9 (Sox9) resulting in
suppression of Ngn3 and retention of a ductal phenotype.16 Conversely, low Notch
signaling was able to activate Sox9 but failed to activate Hes1. Thus Ngn3 was
expressed, and endocrine differentiation was established. In a somewhat
contradictory manner, it has also been observed that mesenchymal presence is
capable of expanding Pdx-1 positive cell populations, likely required to generate
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sufficient numbers of endocrine progenitor cells preceding endocrine terminal
differentiation.17
A number of molecules have been identified in pancreatic mesenchymeinduced signaling including fibroblast growth factors (FGF), which have welldocumented histories in mesenchymal interactions with epithelium, suggested to
play critical roles in mesenchymal-derived notch signaling and subsequent Ptf1a
expression 18, enhance amylase expression 17, and cause significant suppression
of endocrine cell populations

19.

Although, interestingly, FGF7 enhancement has

been observed to increase epithelial growth and result in reduced endocrine
differentiation.20
1.E Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic cancer (PC) is one of the deadliest malignancies, currently on
track to become the second most lethal by 2020. The 2018 projections for PC from
the latest Surveillance, Epidemiology, and End Results Program (SEER) estimate
that over 55,000 new cases will be diagnosed and over 44,000 deaths will occur.21
Despite considerable advances made in diagnostics and therapeutics in the field
of oncology, the goals of early detection of and novel chemotherapeutics for PC
are unmet. With over half of all PC patients diagnosed with distant metastatic
lesions, the 5-year survival rate has remained an abysmal ~10%. Other dismal,
innate characteristics of PC contributing to its substantial lethality while denigrating
the efficiency of therapeutic intervention include low immune cell infiltration

22, 23,

early metastasis

25, 26.

24,

inherent drug resistance

25-27,

and high desmoplasia

Therefore, advances in earlier diagnosis are likely to be most beneficial and
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temporally opportune for PC patients.28 Surgical resection remains the most
successful PC intervention; however, many patients fail to meet the criteria for
surgery making chemoradiotherapy their sole option.26, 28, 29 Still, of the patients
that do qualify for surgical resection, a subset demonstrates poor response and
ultimately succumb to either post-surgical complications or more rapid disease
progression for reasons still unknown.30 Aberrant early onset and progressive
expression of many species of mucins are characteristic of PC.31-35 Within PDAC,
the most prevalent and lethal PC, the tumor mass contains a unique variable and
relatively low population of malignant cells. Much of the bulk of PDAC tumors is
comprised of extracellular components, collagens, and other fibrotic proteins (Fig
1.4).36 The fibrosis has been documented by surgical teams to be so dense that a
core necrotic cyst sometimes develops.36 Furthermore, many pathways have been
demonstrated to be aberrantly altered and may contribute to the high
aggressiveness and lethality of PDAC. Interestingly, many of these dysregulated
pathways are represented in the initial section of this discussion on the
embryological establishment of the pancreas. Many of the histological
observations associated with pre-lesions of PDAC are similar to the differentiation
processes during embryological development and comprise convergent pathways
to PDAC. Pancreatic intraepithelial neoplasm, one of the most recognizable
malignant transformations during PDAC initiation is marked by a degenerative loss
of the ordinarily well-defined apical border of the ductal lumen into a pseudo-brush
border-like, undulating epithelium. Intraductal papillary mucinous neoplasm
(IPMN) are also common initiating conditions for PDAC and possess ductal cells
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Figure 1.4: Pancreatic Ductal Adenocarcinoma

Infiltrating ductal carcinoma of the pancreas presents with characteristic disruption
of cuboidal epithelium morphology and the abundance of desmoplastic stroma.
Green dashes in 4x image mark adenocarcinoma invasion, blue dash marks
adjacent PanIN3 lesion. Black arrows of 10x image indicate invasive carcinoma.
Brown arrow of 20x image indicates the invasive low-grade carcinoma from the
duct.
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FIGURE 1.4: PANCREATIC DUCTAL ADENOCARCINOMA
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with abundant, pale staining cytoplasm containing abundant glycoprotein products
known as mucins. Several mucins (MUC) have become well documented in PDAC
with aberrant and increasing expression. Of exception, MUC1, MUC4, MUC5AC,
and MUC16 have individually been shown to be drastically elevated in a
progression-dependent manner in PDAC cases and may correlate with differential
aggressiveness of tumors.37 Much work is being conducted regarding the use of
mucins as biomarkers.
Arguably one of the most stimulating topics related to PDAC pathology may
be the concept of acinar-to-ductal metaplasia (ADM). Similar to epithelial redifferentiation to mesenchymal cells of the stromal compartment during wound
healing, acinar cells can undergo a reprogramming following pancreatic tissue
insult, but this process is observed to be dysregulated and rapidly occurring in
PDAC.38 Histological presentation of ADM is marked by alteration of the nuclear
shape into a thinner, more flat appearance. This process may represent a reversal
of one of the last stages of functional differentiation in the embryonic pancreas
where the pre-pancreatic cells receive a poised-ductal programming signal from
the notochord initially and the mesenchyme subsequently. The ultimate
consequence of these compartment alterations is that the appreciable architecture
of the pancreas becomes highly disordered with acini, ducts, and islets lose their
defining characteristics. The most well recognized molecular findings in PDAC are
expression of constitutively activated KRAS, loss of Smad4 and p16, and mutated
p53.39 While countless other mutations and aberrant signaling pathways have
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been described, these four persist and often are shown to play roles in “novel”
mutation pathways discovered in vitro and in vivo PDAC studies.
1.F Pancreatic Diseases and PDAC Development
The route from tissue insult to pancreatic cancer is an obfuscated process.
While the link between noncancerous and cancerous conditions of the pancreas
have been postulated and superficially evaluated, the complete picture of the
actual process is yet to be entirely elucidated. These disorders may well contribute
to the pathogenesis of PDAC and require additional investigations to determine
their potential roles in disease biology. As such, these possible involvements
necessitate an introduction to the pathobiology of some common pancreatic
conditions.
1.F.1. Pancreatic Intraepithelial Neoplasia
Pancreatic intraepithelial neoplasms (PanINs) are histologically defined
precursor lesions marked by a progressive disorientation of ductal architecture
(Fig 1.5).40 Due to the histological identification of PanIn lesions, their discovery
often occurs serendipitously in tissue adjacent to resected PDAC tumors. While
literature suggests that PanINs progress into PDAC, likely due to their proximity to
and the histological similarities to PDAC tumors, a lack of consensus regarding
their implication on PDAC aggressiveness or time-to-tumorigenesis is still grossly
lacking.41-43 Interestingly, studies have demonstrated that cells within acinar-ductal
metaplastic (ADM) lesions, characterized by dedifferentiation of acinar cells
observed after pancreatic tissue insult, acquire the commonly PDAC-associated
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Figure 1.5: Histology of PanIN Lesions

A normal pancreatic duct loses its cuboidal morphology in the first step of
transformation to pancreatic intra-epithelial neoplasia. This initial change is
designated PanIN1A, which progresses to PanIN1B when the cells lose polarity.
Low-grade PanIN lesions, classified as benign, progress with loss of basement
membrane (PanIN2) and eventually high-grade PanIN3 with nuclear apolarity,
hyperchromatic nuclei, macronucleoli, and luminal atrophy (black dash focal point
of lesion). In the PDAC Image, high-grade PanINs (blue dash) frequently
associated with invasive carcinoma (black dash).
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FIGURE 1.5: HISTOLOGY OF PANIN LESIONS
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activating KRAS mutations only in ADMs associated with PanINs.44 This driver
mutation acquisition has historically been the attributable factor in defining PanINs
as PDAC precursor. However, new evidence from PanINs and PDAC tumors
resected from patients suggests that the progression to malignancy is not a direct
stepwise progression, but may occur via at least three different pathways.45 In one
scenario, both PDAC and PanIN cells have distinct mutational signatures
indicating that the two lesions arose independently from a common ancestral cell.
The second scenario demonstrated that the same mutations were present in both
PanIN cells and PDAC tumor cells; however, the latter acquired additional
mutations that may have contributed to their malignant transformation. In the third
scenario, the mutational signatures in PDAC and PanIN cells were identical,
implying the mutational burden gave rise to a forward progressive transformation.
Still, understanding the genomic alterations that occur within PanINs and how they
relate to the changes that occur in pancreatic adenocarcinoma cells may
distinguish yet unknown biomarkers and/or therapeutic targets for improved
clinical approaches.
1.F.2. Intraductal Papillary Mucinous Neoplasm
Intraductal papillary mucinous neoplasia (IPMN) is a second histologically
defined precursor lesion of the pancreas in which tumors develop within the ductal
lumen. Approximately 10% of IPMNs progress to invasive PDAC.46 These lesions
are also remarkable in that they produce large quantities of mucins. Acutely,
IPMNs may contribute to symptoms associated with occluded pancreatic ducts and
are frequently appreciable after they progress to mucin-filled ductal cysts.
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Previously termed ‘Mucinous Pancreatic Adenomas’, IPMN lesions are now
classified along a broad spectrum from low-grade mild dysplasia all the way up to
severe invasive carcinoma.47 The radiographic and histological appearances of
IPMNs can be idiosyncratic to their origins and location, but the robust expression
of MUC5AC and punctate expression of MUC1 are typical48. When assessing the
mutational burden of IPMNs, 50% of patient lesions were found to carry KRAS
codon 12 mutations while mutations in the Gα protein subunit was detected in
79%.49 The presence of these mutations may indicate a possible mechanism by
which IPMNs transform into invasive malignancy.
1.F.3. Pancreatitis
Pancreatitis is a multi-faceted disease of variable etiology with elaborate
clinical and laboratory presentations and patient-specific symptomology, aside
from nearly universal upper quadrant pain. However, histological examination of
pancreatitis samples reveals massive fibrosis and collagen fiber deposition,
alongside fat and parenchymal necrosis visible by gross pathological
examination.50 The underlying mechanism contributing to the development of
pancreatitis is thought to be the premature activation of zymogens or digestive
enzymes.50
About the several sub-classifications of pancreatitis and specialized
diagnostic approaches to each one, indistinguishable alterations in stromal
composition, fibrosis, and scarring (in the most advanced cases) persist as the
universal histological characteristics of all subtypes. Of note, however,
autoimmune pancreatitis demonstrates a unique case of histological distinction in
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that the infiltration of leukocytes contributes to an appreciable difference in the
tissue appearance. Further, depending on the mode of immune infiltration,
additional dissimilarities become apparent with inflammation contributing to fibrotic
alterations of ductal basement membranes or the generation of fibrotic lobules. As
in the case of all other forms of pancreatitis, histological clues inferring the stage
of progression may be apparent when considering the cell density and degree of
fibrosis at presentation (Fig 1.6)51. The ultimate and most notable presentation of
fibrosis is the generation of vacuole-like gaps in stroma as the collagen is
crosslinked and becomes progressively more irregular and denser. These gaps
may appear at any location throughout the pancreas from the surface and deeper
following the deposition of collagen.
The clinical presentation of pancreatitis is varied but most often includes
intense pain in the middle upper abdomen and digestive malabsorption. The most
intense pain coincides with the historically labeled acute pancreatitis (AP) and is
associated with a near 10% mortality

52.

An interesting area of focus is the

transition from AP to chronic pancreatitis (CP), which occurs in approximately 7%
of AP cases with 11-15% of AP patients presenting with a recurrent AP attack
54.

53,

Currently there is a transition to contract the understanding of AP and CP as

distinct conditions but rather ranges of severity of the same diagnosis. Still, the
clinical presentations, risks, treatments, and outcomes of AP are grossly different
from CP.55 As such, the two terms now have distinct use in clinical management
with restricted use in pancreatitis research. AP patients have rapidly increased
pancreatic enzyme premature activation coinciding with pancreatic cell necrosis.

42

Figure 1.6: Histological Features of Pancreatitis

The progression of pancreatitis produces histology that transitions with disease.
Cell-rich, storiform fibrosis observable during early pathology. Large focal areas of
architectural disruption are hallmarks of sustain pancreatitis (black arrows). With
chronic disease, a prolonged immune infiltration and inflammation (red circle of
insert) become notable. The protracted inflammation results in intense fibrotic
scaring and consist primarily of collagen fibrils and reduced cell populations. Blue
arrow of insert image indicates PanIN2 with possible concurrent IPMN.
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FIGURE 1.6: HISTOLOGICAL FEATURES OF PANCREATITIS
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The condition induces a strong systemic inflammatory reaction and, at its most
severe, leads to multiorgan failure and death. CP typically occurs with less severe
pathology but over many years compared to days with AP. The prolonged tissue
insult in CP results in slow loss of pancreatic function, contributing to poor digestive
abilities, nutritional deficiencies, and diabetes. Additionally, the rate of pancreatic
cell loss or turnover most frequently associates with pancreatic fibrosis compared
to necrosis in AP. Therapeutic approaches to AP usually involve pain management
and fluid support, whereas intermittent fasting, lifestyle changes, and partial
pancreatic resection can all be indicated treatment for CP.
Substantial research has investigated the risk factors associated with
pancreatitis. Nearly 80% of acute attacks of pancreatitis diagnoses are related to
alcohol use or the presence of gallstones.54 While other physical risks contributing
to pancreatitis have been identified, such as drug use and obesity, reported
statistical assessment of these risks varies among studies and across
geographical regions. However, emerging evidence has suggested that the use of
smoking tobacco may impart a risk of pancreatitis greater than that observed with
binge alcohol abuse.56 Finally, several genetic variations have been linked to
lifelong risk of pancreatitis. Extrapancreatic factors, like genomic variations in
alcohol dehydrogenase or aldehyde dehydrogenase genes, are associated with
altered ability to metabolize alcohol effectively, while other variants in pancreatic
associated genes, such as trypsinogen and Serine Peptidase Inhibitor Kazal Type
1 (SPINK1) among others, may constitute premature enzyme activation or
reduced/inhibited secretion of digestive enzymes.57
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1.F.4. Diabetes
Diabetes mellitus is a chronic condition marked by glucose uptake
dysregulation affecting approximately 8.5% of the global adult population,
according to the World Health Organization.58 Historically identified as a hormonal
disorder, research has demonstrated that diabetes is more a systemic disorder
affecting everything from neural health, to vascular function, to immune response,
and tissue healing processes. While some minor forms exist, diabetes is
predominantly classified into two major categories: Type I and Type II.
Type I diabetes mellitus (TIDM) is most easily explained by the immunemediated destruction of the pancreatic insulin-producing beta cells (β-cells) in the
islets of Langerhans. Importantly, inflammation has been suggested as the most
influential contributor to β-cell degradation. Due to lack of an available detectable
biomarker, knowledge of the initiation and progression of the disease is severely
incomplete. Clinicians do know, however, that destruction of pancreatic β-cells
follows an observable infiltration of lymphocytes into islets59 and upregulation of
insulin-positive β-cell-associated human leukocyte antigen (HLA-ABC)60. This
presentation, known as insulinitis, has been documented in up to 23% of insulinpositive islets in 78% of recent-onset type 1 diabetes patients.61 Following the
elevation of HLA expression in islets, detection of insulin-positive endocrine cells
is drastically reduced. Consequentially, patients experience a profound, lifealtering symptomology associated with type 1 diabetes. Systemic insulin levels are
critically depleted, and maintenance of normal-ranged serum glucose levels
depends exclusively on routine post-prandial administration of pharmaceutical
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recombinant insulin, frequent blood glucose checks, and often the use of glucose
supplements to rescue dangerous drops in serum glucose because of impaired
glucagon function.
Type II diabetes mellitus (TIIDM) may easily be viewed as an entirely
separate disease than TIDM, in that pancreatic β-cells are present within islets and
produce insulin during the initial phase and but quickly deplete as systemic
resistance to insulin signaling drives β-cells to exhaustion and islet inflammation
increase.62 This increased inflammation is one of the histological hallmarks of a
TIIDM pancreas and has been shown to be stimulated, at least in part, by
increased production of interleukin-1β (IL-1β) from pancreatic islet β-cells exposed
to prolonged, high levels of serum glucose.24 This abundant IL-1β mediates two
distinct responses: one, β-cells experience a subsequent upregulation in NF-ΚB
transcriptional activity and Fas-elicited apoptosis; and two, islet-resident
macrophages expressing receptors for IL-1β induce inflammasome formation,
contributing to and sustaining an inflammatory environment. Furthermore,
secretions of islet amyloid polypeptide (IAPP; pre-cleaved peptide co-secreted
with insulin) from β-cells have been hypothesized to contribute substantially to
amyloid plaque deposition in diabetic islets, even when insulin-deficient β-cells
persist in the pancreatic islets.63
The connection between diabetes and PDAC is not straightforward;
however, evidence suggests a calculable risk exists between the two. Metaanalysis has shown that longstanding diabetes coincides with a nearly 2-fold
increase in PDAC development risks over an individual’s lifetime, while newly
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diagnosed diabetes elevates the risk to as high as 8-fold.64 The calculated risk of
PDAC development with new-onset diabetes is now used as a clinical predictor
indicating higher PDAC screening in older individuals known as the ENDPAC
model.65 Independent validation of ENDPAC scoring further identified concurrent
weight loss as a risk factor of clinical importance raising the baseline prevalence
of PDAC in control subjects from 0.78% to 1.7% in comorbid patients.66 While the
determinants between PDAC and diabetes overlap, the underlying pathways
contributing to both conditions are important areas for future research.
1.G Alternative Splicing in Cancer
Modern concepts of cancer have focused on the concepts of precursor
conditions,

acquisition

of

mutational

burden,

uncontrolled

proliferation,

desmoplasia, immune modulation, and altered cellular metabolism. However,
developments in technologies and increasing computational power have advanced
our ability to begin to decipher the complex cell transcriptomes. Next-generational
sequencing has revealed a staggering array of RNA splice variants in all
malignancies, but the significance of their functions or pathological relevance are
poorly understood for the most part. At present, up to 95% of the 20,000-25,000
human genes are believed to undergo alternative splicing.67 While the mis-splicing
of critical genes might seem to be an insulting cellular event, it may actually be
beneficial to life by providing the templates for a substantial number of potentially
advantageous novel proteins. Alternative splicing has been attributed to
physiological homeostasis within cells, most famously with the splicing of Bcl-x of
the Bcl-2 family with the shorter isoform (Bcl-xS) contributing to apoptosis and the
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longer isoform (Bcl-xL) having counter, antiapoptotic functions.68 Still, a higher
prevalence of alternative splicing in cancers has been observed many times.69-72
This suggests that cancers capitalize on the random accumulations of genetic
lesions and aberrant splicing which contribute to proteomic neofunctionalism to
promote survival and aggressiveness.73-80 Additionally, tumor cells may use these
novel proteins for other aspects, such as regulatory decoys, metastasis, immune
evasion, or therapeutic resistance. This further leads to the question of potentially
targeting these new alternative transcripts clinically for diagnosis, prognostic
consideration, or treatment. While a few notable alternatively spliced genes have
been well studied regarding their function and specific expression in cancers, the
majority remain obscure. While the field of cancer-specific splicing continues to
develop, several considerations require attention, including altered mechanisms of
splicing (i.e., splice site mutations, mutations in spliceosomal components, altered
expression of spliceosome-associate proteins, or preference for U12-minor
splicing), cancer-type specific expression of alternate splices, and functionality of
novel splices. Here, I will review the most recent studies investigating the structure
of the spliceosome, mechanisms of splicing, and cancer-specific alternatively
spliced genes with the intention of identifying potential splice variants of interest
for diagnosis, prognosis, or therapeutic targeting.
1.G.1. Modes of Splicing
Splicing of the pre-messenger RNA (pre-mRNA) is a well-documented and
vital process of cell biology. There are around 30,000 known genes coded in the
Homo sapiens genome representing roughly only 1% of the prodigious 3 billion
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base pairs organized into 23 pairs of chromosomes. The remaining 99% of the
genome is comprised of intragenic non-coding sequences and intergenic introns
that separate the exons of the final protein coding sequences. While these intronic
sequences present a seemingly dilemmatic problem for the study of genomic
sequences of proteins, it is well recognized that inclusion of these additional bases
provides adaptive potential to organisms from an evolutionary perspective. Several
types of splicing scenarios to account for the inclusion introns or exclusion of exons
have been reported (Fig 1.7).81
1.G.2. Processivity of the Splicing Reaction
To understand the errors of splicing and the associated consequences, a
review of the spliceosome, or splicing machinery complex, and the reactions it
facilitates are necessary. The mechanisms of RNA splicing have been well
investigated in vitro and processing ‘decisions’ by the cell to use the major or minor
splicing machinery are determined by the exon-adjacent intronic sequences,
though the general reactions overlap between the two pathways requiring 5 small
nuclear RNAs (snRNAs) for both splicing classifications which interact with as
many as 170 nuclear proteins82 to form small nuclear ribonucleoproteins
(snRNPs). The snRNAs facilitate RNA-RNA and RNA-protein interactions while
the proteins of the snRNPs are responsible for the stabilization of the spliceosome
complexes and catalytic processes of splicing. In a regulated, stepwise set of
interactions and reactions, four intermediate complexes are formed before the final
spliced exon product and the cleaved intron are released (Fig 1.8).83 The general
process of intronic splicing, undergone concurrently with transcription, is
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Figure 1.7: Modes of Splicing

Schematic diagram depicting the various methods of splicing events that
potentially exist in cells. Under normal splicing regulation, introns are removed,
and all coded exons are ligated to form the final sequence of the mature
messenger RNA. Some introns may be included in the final sequence due to missplicing, consequently altering the structure and potentially ameliorating the
translatability of a (dys)functional protein. Mutual exclusion of exons seems to be
an evolutionarily retained mechanism which allows a single gene to code for
multiple functional proteins. Under mutual exclusion, the two affected exons are
never retained in the final mRNA together. Exon skipping is the exact opposite of
intron inclusion whereby an entire exon is removed within the lariat loop. Finally,
the presence of cryptic splice sites can alter the pivot points of the spliceosome
and alter the final coding sequence of the resulting mRNA.
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FIGURE 1.7: MODES OF ALTERNATIVE SPLICING
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Figure 1.8: Intermediates of RNA Splicing

Splicing of pre-mRNA generates 4 intermediate species. Recognition of the 5’
splice site by U1 initiates splicing and generates Complex E. The recruitment of
U2/U2AF upstream of the 3’ splice site sequence establishes Complex A and
primes the pre-mRNA for structural rearrangement. Binding of the tri-snRNP
U4/U5.U6 folds the RNA creating the lariat loop of Complex B. Release of U1 and
U4 brings the catalytic domains of the spliceosome to the RNA creating Complex
C. Cleavage and ligation of the ribose backbone fuse the adjacent exons and the
spliceosome disassembles.
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FIGURE 1.8: INTERMEDIATES OF RNA SPLICING
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mechanistically the same and involves the recognition of the 5’ splice site
sequence, invariable adenine within the branch point, and the 3’ splice site
sequence (Fig 1.9). Following the formation of the lariat loop, two esterification
reactions release the intron and bond the retained exons. While the mechanisms
of major and minor splicing are the same, the initiation of splicing is different
between the two.
1.G.3. Spliceosomal Complexes and Functional Mechanisms
The major spliceosome, as its name suggests, is the most frequent method of RNA
splicing. The 5’ splice site is recognized and bound by snRNP U1 forming the first
intermediate Complex E. The splicing factor U2 Auxiliary Factor (U2AF) complex
binds the polypyrimidine sequence upstream of the 3’ splice site. In an ATPdependent manner, the snRNP U2 binds the pre-mRNA just upstream of the U2AF
binding site to form the second intermediate Complex A. Next, the U4/U5.U6
complex engages the spliceosome with U4 unwinding and U6 undergoing a
conformational transformation upon interacting with the 5’ end of the intron. U6
binds U2 at the 3’ end forming a lariat loop while U5 binds the junctional ends of
the adjacent exons establishing Complex B. U1 and U4 are displaced to form
Complex C as the spliceosome prepares to perform two esterification reactions at
the adjacent exonic sequences. The exons are ligated as the lariat intron is
released and the splicing machinery disassembles.
A small population of introns demonstrate sequences at the 5’ (AT) and 3’
(AC) splice sites that deviate from the recognized and bound sequences described
above and entirely absent of the polypyrimidine sequence.84 It was found that the
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Figure 1.9: Two Principal Splicing Sites

The consensus sequences of the 5’ and 3’ splice sites differ between two
predominate pre-mRNA classes. The contained sequence determines if the RNA
is spliced via the major or minor spliceosome pathway by the recruitment and
binding of spliceosomal-specific snRNPs and associated binding proteins. The
blue boxes highlight the major spliceosomal sequences while red boxes indicate
minor spliceosomal sequences. Internal black boxes indicate the consensus
binding sites. The order (top to bottom) and size of each base letter indicates the
relative proportion at that site.
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FIGURE 1.9: TWO PRINCIPAL SPLICING SITES
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processing spliceosomes of these introns contained the low frequency U11 and
U12 instead of U1 and U2/U2AF. In this minor splicing reaction, U11 dissociates
from U12 to bind at the 5’ site while U12 binds the 3’ site forming Complex E and
Complex A, respectively. The lariat loop of Complex B is formed when the trisnRNP U4atac/U5.U6atac dissembles allowing U6atac to binds the 5’ site,
undergo a dynamic transformation, and bind U12 while U5 stabilizes the junctional
sequences of both exons. U11 is displaced forming Complex C. The same two
esterification reactions cleave the intron and ligate the exons releasing the lariat
intron before the spliceosome complex disassembles.
1.G.4. Aberrations in Splicing and Spliceosomal-Associated Proteins
While splicing is strongly credited with providing cells with crucial adaptive
abilities and superior gene expression regulation during embryologic development,
it is also heavily involved in disease processes. Alternative splicing is generally
accepted to be the consequence of several different errors. The first group of
possible causes are mutations of the key splicing regulatory domains called cisacting elements and include the core consensus sequences (5’ and 3’ splice sites
and the branch point) and splicing enhancers or silencers located in the intronic or
exonic sequences. These mutations can be within the genomic sequence or a
read/write error in the transcription of messenger RNA (mRNA). Several
pathogenic conditions have been associated with mutations in cis-element
sequences leading to mis-splicing of the disease-related mRNA. One of the most
described involves mutation in the dystrophin gene, expressed mostly in muscular
and skeletal cells, and causes a family of X-linked conditions called Duchenne and
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Becker muscular dystrophy. Dystrophin is expressed in three functional isoforms
based on the presence of independent promoters.85 However, point mutations in
the dystrophin gene contribute to many alternative truncated or frameshifted
isoforms of final mRNA contributing to the progressive loss of neuromuscular
function. Around 25% of dystrophin mutations involve changes in splice site
sequences.86 The mutation HBB110G>A contributes to the creation of an incorrect
3’ splice site and causes the very well-known disease β-thalassemia.87 Many
mutations in cis-elements of the intermediate filament lamin A/C gene LMNA lead
to mis-splicing of the several LMNA mRNA expressed from the single locus and
have been linked to upwards of 14 different diseases ranging from muscular
dystrophies to cardiomyopathies.88-92 In many of these aforementioned diseases,
gene therapies are being investigated to modify the spliced mRNA products and
have shown great promise for potentially successful treatment of afflicted patients.
The second classification of aberrant splicing is caused by mutations within
the core spliceosome-associated proteins. While it is intuitive that mutations in
splicing associated proteins may have horribly negative consequences, the
number of proteins involved in spliceosomal complexing and function in
combination with incomplete penetrance makes predicting outcomes of such
mutations a difficult achievement. Diseases associated with spliceosome
mutations are more rare owing to the vital nature of its function. However,
mutations in pre-mRNA processing factor genes (PRPF) have been documented
to interfere with U4/U5.U6 tri-snRNP complex formation, causing several
conditions involving mis-spliced genes. One of the more completely described of
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these mutations is found in PRPF6, leading to the inhibition of U4/U6 interaction in
retinitis pigmentosa.93
The third class of splicing-affected mutations involve those in trans-acting
splicing factors. Owing to the involvement of splicing factors in the recruitment of
the core spliceosome to pre-mRNA, alterations in sequence or concentrations of
extrinsic trans factors can have complex consequences on the final mRNA
sequences. More directly, these consequences involve inclusion of introns or
exclusion of exons constituting changes in functional domains of the translated
protein. Because splicing factors’ functions are intrinsically linked to their structural
motifs, modifications in trans-acting factors can fail to recruit spliceosome snRNPs
to either splice site by mutation-induced loss of protein interactions or can mask
the splice sites altogether. An example of conditions caused by this type of
dysregulation is the infamous amyotrophic lateral sclerosis, more specifically,
familial hereditary ALS. Chromosomal expansion of a G4C2 sequence in the
C9orf72 has been suggested to sequester splicing factors contributing to a global
dysregulation of pre-mRNA splicing.94 Still, other ALS-associated mutations of
splicing trans factors can have damaging consequences on the splicing of other
spliceosome proteins, such as the heterogenous nuclear ribonucleoprotein P2
coded by the FUS gene. FUS is involved in the splicing of numerous genes, one
of which is U1.95
1.G.5. Alternative Splicing in Cancer
Relevant to the direction of this dissertation, alternative splicing is heavily
involved in cancer biology. RNA-sequencing studies have linked the abundance of
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alternative splicing events in cancer cells to the abnormal elevation of premature
stop codons found in RNA of cancers compared to normal cells.96 Indeed, a recent
expansive pan-cancer study demonstrated that cancers possess nearly 20% more
alternatively spliced RNA than normal cells.97 The discovery that many point
mutations in cancers are linked to loss of splice site sequence combined with the
more recent finding that cancer-specific mutations generate novel splice sites
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leads to the question of why these cells are not targeted by immune surveillance
cells for destruction. Interestingly, this same study found that many of these
splicing affected mutations were found in immune checkpoint genes including
those involved in PD1-PDL1 pathways. However, other examples of the previous
classes of splicing dysregulation are also abundant in cancers.99 Sequencing
analysis of hematopoietic cells revealed mutations in the U2AF1 gene and
contributed to an accumulation of mis-spliced mRNA in cells of several
hematologic malignancies.100, 101 While the presence of these mutations in cancers
are of interest, more relevant is the contribution these genomic alterations make
to the pathologies of their respective disease states, of which many groups have
written very succinct analyses.81, 99, 102, 103 Some more notable examples involve
many aberrant alternative splice sites in the master cell cycle regulator Tp53
consequentially reducing the anti-proliferative response of p53
alteration in apoptosis by alternative caspase 2

105

and caspase 8

104,
106,

bimodal

enhanced

cell mobility by altered interaction of macrophage-stimulating protein receptor and
Recepteur d’Origine Nantais 107, 108, and promotion of angiogenesis by mis-splicing
vascular endothelial growth factor A

109, 110.
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direct consequences on malignant processes are described as most interesting
because these cancer-specific sequences lend themselves to the development of
novel diagnostic detection methods and targeted therapeutic strategies, as
discussed in the next section.
1.G.6. Possible Advantageous Use of Alternatively Spliced RNAs
While detection of alternative splicing per se is unhelpful, the identification
of cancer-specific alternative splice variants as biomarkers has the potential to
tremendously progress our ability to diagnose malignancies in patients early and
potentially increase the likelihood of a successful intervention. Mutational analyses
of many genes have highlighted involvement in diseases, and now a growing body
of evidence is emerging on splice variants, whether from genomic mutation or
afflicted splicing regulation.111 The tumor suppressors BRCA1 and BRCA2 are
frequently implicated in many malignancies, including cancer of the breast, ovary,
and pancreas. A Breast Information Core database analysis of BRCA1 and BRCA2
demonstrated that nearly 5% of their alterations in breast cancer were due to
alternative splice site utilization.112 Importantly, however, the expression of
alternative splice variants is found throughout the body in many tissues. Therefore,
the specificity of a particular variant in tissues of interest must be weighed against
its expression in non-target tissues for its use as a relevant biomarker. For
example, an investigation of the variant BRCA2Δ12 was found expressed 33%
higher in hormone-negative breast tumors compared to normal breast tissue.113
The discovery of prostate-specific antigen (PSA), encoded by the kallikrein-3
(KLK3) gene, has revolutionized our clinical ability to screen and monitor men for
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the development and progression of prostate cancer. However, other conditions,
such as prostatitis or benign prostate hyperplasia, can cause detectable elevations
in PSA. Alternatively, studies looking at KLK genes expressed in prostate cancer
have found that low expression of the prostate-specific KLK11 correlated with a
more aggressive disease.114
Detection of splice variants for diagnostic purposes would be a massive
clinical advancement; however, detection of these variants plausibly benefits those
diagnosed in early disease. Therefore, the therapeutic targeting of cancer-specific
splice variants stands to benefit those unlucky to receive advanced stage
diagnoses. Employment of alternatively spliced RNA targeting will require
extensive consideration and study as the consequences of many are unknown or
under investigated. Methods of capitalizing on alternative splicing may involve the
design of small molecules to counteract the effects of biologically active variant
proteins or targeting and neutralizing the variant mRNA itself.80 One very promising
example of the latter is the use of splice-editing antisense oligonucleotides in
Duchenne muscular dystrophy. DMD is a complex disease containing few deletion
events resulting in a truncated dystrophin protein. A very common mutation in
dystrophin causes a frameshift mutation in exon 51. Studies have used a few
antisense oligonucleotide molecules (drisapersen, eteplirsen, and golodirsen) to
mask and induce subsequent skipping of exons 51 and 53, contributing to a
truncated but functional dystrophin protein.115, 116 These therapeutic techniques
require substantially more study but have shown promise in early clinical trials. An
emerging concept in cancer intervention is the role splice variants may play in
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therapeutic resistance in tumor cells. The presence of a point mutation in the BCRABL fusion protein (caused by chromosomal rearrangement found in chronic
myeloid leukemia and other cancers) contributes to the alternatively spliced BCRABL35Ins.117 This variant has been linked to poor response to the first-line therapy
imatinib, a tyrosine kinase inhibitor, due to a loss of a drug-binding site in the
variant’s modified conformational shift.118-120 The loss of function of BRCA1 and
BRCA2 in tumor cells forces a reliance on poly-ADP-ribose polymerase (PARP) to
repair DNA strand breaks for genomic integrity. Some clinical trials are exploring
the use of PARP inhibitors as chemotherapeutic sensitizers in BRCA1/2 deficient
cancers with some success.121-123 Other strategies to directly correct mis-splicing
are also hypothesized to have significant benefits. A mutation in the BRAF gene
(BRAFV600E) is highly implicated in the aggressiveness of the skin cancer
melanoma, present in around 60% of patient tumors.124 Treatment of BRAFV600Eexpressing melanomas frequently involves BRAF inhibitors. However, some tumor
cells express a truncated variant that skips exons 4-8. This variant is not bound by
BRAF inhibitors, due to modification of its ATP-binding site. The use of
spliceostatin A analogues has been suggested to target the trans-acting factor
SF3B1 thereby inhibiting the formation of the core spliceosome snRNP U2-SF3B1
complex.125 This approach has demonstrated the ability to prevent exon skipping,
therefore recovering BRAF inhibitor sensitivity.80, 126 With each study published,
strategies to correct the inbuilt advantages that alternative splicing may provide to
cancer cells evolves, but we still have much left to uncover.
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1.H Mucins
Mucins are large glycoproteins containing compulsory tandem repeat
domains with complex carbohydrate branches enzymatically added through a
series of post-translational reactions (Fig 1.10).33 Class-wise, mucins are sorted
into two distinct groups: transmembrane or secreted. Physiological expression of
mucin is apically observed on epithelial cells, especially in the respiratory mucosa
and gastrointestinal tract. The functions of mucin include establishing a physical
barrier and mediating cell-cell and cell-stroma interactions, cell signaling, and cell
migration.
1.I Mucins in PDAC
The role of mucins in PC disease biology has been reported extensively,
including their contributions to cell migration and metastasis 127-131, proliferation 127,
128, 130-133,

and drug resistance

26.

With recent advances in high-throughput

transcriptomic sequencing and bioinformatics techniques, we now know that
cancer cells demonstrate elevated levels of alternative splicing.
136

70, 73, 80, 102, 103, 134-

It is unclear whether spliceosomes act aberrantly, are guided to key splicing

sights, or become overwhelmed by transcriptional machinery. However, the
expression and detection of disease-specific isoforms hold incredible diagnostic
and therapeutic promise.

73, 80, 136

Furthermore, mucins demonstrate numerous

alternatively spliced isoforms which can alter the many functional domains coded
in their proteins.133,

137-141

The Cancer Genome Atlas (TCGA) is a significant

resource to assess cancer patient-derived tumor transcriptomes. Through TCGA,
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Figure 1.10: Structural Motifs of Mucins

(Top) Mucin structure demonstrates the large architecture of membrane-tethered
mucins and their extensive glycan branches. (Bottom) Secreted mucins contain
similar structural motifs as transmembrane mucins but lacking the transmembrane
domain.

Used with permission, Kaur, Kumar, Momi, Sasson, and Batra. Mucins in Pancreatic Cancer and
Its Microenvironment. Nat Rev Gastroenterol Hepatol, 2013. 10(10): p. 607-20. (Appendix A-4)
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FIGURE 1.10: STRUCTURAL MOTIFS OF MUCINS
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researchers have access to large, relatively organized cancer cases including
RNA-sequences (RNA-seq), mutation and aberrant chromatin remodeling, and
matched clinical data.
Aside from mucins, several other mutated genes have been ascribed to PC.
The most consequential and frequently detected mutation in PC is a constitutively
active KRAS mutation contributing to unchecked proliferative signaling via the
MAPK pathway or cell growth and anti-apoptotic signaling via the PI3K cascade
and observed in over 90% of PC tumors.

22, 142

Abrogation of KRAS signal has

been postulated to yield significant benefits to PC patients. Mutations in TP53,
observed in approximately 70% of PC tumors, further dysregulate PC cell
proliferation. Similarly, the tumor suppressor cyclin-dependent kinase inhibitor 2A
(CDKN2A), which codes for p16 and p14arf, is commonly mutated

22, 142,

also

contributing to unrestrained cell proliferation.
Relative to survival benefits achieved in other cancers, pancreatic ductal
adenocarcinoma (PDAC) continues to rise in both incidence and mortality with a
5-year survival rate of 10%.
including late diagnosis

145

143, 144

The underlying causes are multi-factorial,

due to lack of sensitive biomarkers

146,

inadequate

therapeutic options 147-149, asymptomatic progression 150, and early metastasis 151,
152.

One of the earliest and most explored events in cancer is rewiring of the cellular

pathways subverting physiological gene inactivation 153-156. This process is evident
in the aberrant expression of mucins in PDAC. The large glycoprotein family of
mucins has been widely implicated in many aspects of PDAC biology, including
progression 31, 157, metastasis 158-160, and drug resistance 161-163. Still, no studies to
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date have comprehensively investigated the full expression profiles of mucins in
PDAC or their involvement in patient survival.
Further rewiring of cellular pathways is facilitated by the high processivity of
genetic information during cancer progression. This leads to the appearance of
abundant and novel alternatively spliced mRNA species

164.

Alternative splicing

includes many possible modifications to the mRNA transcripts, including exon
exclusion or intronic inclusion, due to the use of cryptic splice sites or splice site
masking 165, 166. These modifications alter the functional domains in the translated
proteins and contribute to neo-functionality or elimination of regulatory domains 78,
79, 167.

Therefore, this increased proteomic repertoire is hypothesized to impart a

substantial benefit to malignant cells. Many of these alternatively spliced variants
(SVs) are cancer-specific and may represent reliable biomarkers for prognostic or
diagnostic purposes 75, 168. Investigations of mucin alternative splicing in PDAC and
its role in pathology and targeting have been limited to MUC1 and MUC4 SVs with
severe truncation of tandem repeats or MUC1 cytoplasmic domain activity 138, 141,
169, 170.

Given the expression of MUC1 in healthy pancreatic tissues, studies of

other mucins, including MUC4, MUC5AC, and MUC16 alternative transcripts,
might be more impactful in PDAC, as these mucins are expressed explicitly during
oncogenesis 31, 33. Mainly, MUC4 expression is unique to PDAC, notably absent in
normal or nonmalignant inflammatory conditions of the pancreas

151, 171, 172.

No

studies have been published to date exploring the link between mucin SVs and
survival outcomes in PDAC patients.
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Another problem related to PDAC is the one-size-fits-all clinical approach.
The evolving field of cancer therapy has greatly benefited from the identification of
cancer subtypes

173-175,

which has aided in the therapeutic success in several

malignancies, with breast cancer undoubtedly being the most impacted

176, 177.

Subtyping strategies of PDAC tumors have been reported in three principal studies
and reflect transcriptomic analysis of whole tumor 178 or virtual microdissection 179,
or genomic analysis

22.

These approaches, while meritorious for addressing an

underexplored area of PDAC, suffer from drawbacks affecting their widespread
utilization in the clinic, namely the need for expensive sample processing and
significant computational analysis.
1.J The Cancer Genome Atlas
Modern advances in cancer discoveries wield substantial power levied
from next-generational sequencing technologies combined with matched clinical
history. The increase in computing power over the past decade has tremendously
empowered our ability to screen entire transcriptomes of many patients to identify
putative biomarkers and prognostic indicators. Second to the Human Genome
Project, a joint effort by the US National Cancer Institute and the US National
Human Genome Research Institute in 2006 resulted in the Cancer Genome Atlas
(TCGA). TCGA represents arguably one of the most important databases for
cancer bioinformatics ever compiled. Contained within the publicly available TCGA
servers is more than 2.5 million gigabytes of genomic, transcriptomic, proteomic,
epigenetic, and clinical data from over 20,000 primary tumors and normal tissue
samples in 33 cancer types. While many incredible discoveries have already been
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described from its data, TCGA is humanity’s first major step towards a
collaborative moonshot cure for cancer.
1.K TCGA PDAC Characterization
The initial assessment of the 150 PDAC samples uploaded to the
pancreatic cancer dataset (PAAD) to TCGA was conducted by Raphael et al. of
The Cancer Genome Atlas Research Consortium.142 An in-depth analysis of the
genomic and transcriptomic profiles of the included patient samples revealed a
wealth of information about the cellular alterations occurring in PDAC tumors and
is credited with establishing our clinical knowledge about the driver and passenger
mutations associated with the disease (Fig 1.11). Over 90% of tumors sequenced
demonstrated missense mutations coding for constitutively activated oncogenic
KRAS, with G12D being the most prevalent at nearly 45% of detected KRAS
alterations. Only 4 patients demonstrated KRAS amplification. Several tumor
samples also demonstrated multiple KRAS mutations throughout the tumor
sample while few samples were assessed at the single cell level revealing multiple
mutations of KRAS in the same cell. Interestingly, in the ten KRAS wild-type
samples, other unexpected driver mutations were discovered including GNAS
(n=3), CTNNB1 (n=2), and BRAF (n=2). Six of these 10 samples were found to
have MAPK pathway activating mutations downstream of KRAS, potentially
abrogating the need for KRAS activating mutations. The frequently cancer
associated Tp53 was mutated in over 70% of the samples. One of the most
influential aspects of this study was the assessment of PDAC tumor cellularity. The
tumor ratios were scored for all samples by pathologists upon
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Figure 1.11: Genomic Profiling of PDAC Tumors from TCGA

Integrated genomic data for 149 non-hypermutated samples (columns), including
mutations (Truncated, In-Frame, or Missense), amplifications and homozygous
deletions (‘‘Deep Deletion’’), fusions derived from mRNA data, and germline
mutations for selected genes as described in the text. Overall number of
mutations/Mb and clinicopathologic data for each sample are shown as tracks at
the top. Significantly mutated genes (q % 0.1) from exome sequencing data listed
in order of q value, followed by other recurrently altered genes organized in
functional classes of oncogenes (Red), DNA damage repair genes (Green), and
chromatin modification genes (Blue). Significantly mutated genes from these
classes are colored accordingly. The percentage of PDAC samples with an
alteration of any type is noted at the left.

Used with permission, Cancer Genome Atlas Research Network. Electronic Address and Cancer
Genome

Atlas

Research.

Integrated

Genomic

Characterization

of

Adenocarcinoma. Cancer Cell, 2017. 32(2): p. 185-203 e13. (Appendix A-5)
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FIGURE 1.11: GENOMIC PROFILING OF PDAC TUMORS FROM TCGA
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submission of sample to the study. The degree of difference between the samples
was minimal by pathologist assessment. The team, however, used an in-silico
method (ABSOLUTE Algorithm) to compute purity scores and revealed a
stratification that differed greatly from pathologists (Fig 1.12). The implications of
the range of malignant cellularity scores on PDAC next-generational sequencing
analyses are far reaching and demand significant consideration in future studies.
The TCGA Consortium further assessed tumor purity and gene signatures for
PDAC subtyping and compared to three dominant stratification strategies
presently used. An exploration of those subtyping methods, their genome or
transcriptome signatures, and relationship with tumor sample purity is addressed
in the following section.
1.L PDAC Subtyping
Cancer subtyping has greatly influenced the trajectory of the clinical
approach to oncology. Diagnostic, prognostics, and therapeutic interventions are
all benefiting from a targeted application to unique subtypes of cancers. As
addressed numerous times, the advancement of technologies and computational
processing power have significantly empowered researchers’ abilities to begin
segregating cancers into subtypes, often with drastically different pathobiology and
indicated treatments. Undoubtedly, substantial work lies ahead to begin to
elucidate the major aspects of this field, but some cancers are already benefiting
immensely from this work. The best example of the clinical progress facilitated by
gene expression-based subtyping is breast cancer (BC). Previously, clinical BC
typing was based on classification built on the collective physical parameters of
74

Figure 1.12: Assessment of PDAC Tumor Purity

Samples submitted to TCGA for inclusion with the PDAC dataset were initially
screened by pathologists for tumor sample purity. These scores were compared
to two different computational methods of assessing tumor cellularity. While Mode
methylation was near the quartile range and median as the ABSOLUTE method,
its segregation of samples into High and Low purity were similar to that reported
by pathologists. In both cases, few samples cross the medians into the opposite
purity zone. The ABSOLUTE algorithm was selected as the most reliable predictor
of tumor sample purity.

Used with permission, Cancer Genome Atlas Research Network. Electronic Address and Cancer
Genome

Atlas

Research.

Integrated

Genomic

Characterization

of

Adenocarcinoma. Cancer Cell, 2017. 32(2): p. 185-203 e13. (Appendix A-5)
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FIGURE 1.12: ASSESSMENT OF PDAC TUMOR PURITY
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tumors (dimensions, location, nodal status, grade) and histological assessment
(HER2 overexpression, estrogen [ER] and progesterone [PR] receptor status).
Comparing

the

immunohistochemistry,

tumor

classifications

were

established from a ‘diagnostic tree’ yielding four subtypes using luminal+/(hormone receptor expression) and HER2+/- status, and basal+/- status for
luminal-/HER2- tumors (ER-/PR-/HER2- tumors are termed Triple Negative and
further subtyped by expression of basal markers). A large cohort meta-analysis
uncovered significant differences in survival and responses to therapeutic
modalities between the five subtypes.180 These early investigations into BC
subtyping and the elucidation of HER2 overexpression and amplification effects
contributed to development of the revolutionary class of HER2/neu antagonist
drugs and substantial increase in survival of these affected BC patients. Still, BC
subtyping continues to benefit from gene sequencing studies.181 Sequencing
studies comparing gene expression signatures of breast tumors in murine models
to human tumors revealed many previously uncharacterized genes with potential
targeting applicability and a novel subtype marked determined by low expression
of the tight junction family claudin.182 The claudin-low tumors were found to have
epithelial-mesenchymal

transition

signatures183,

mammary

stem

cell-like

features184, and tumor initiating properties185. While investigations into BC
expression signatures are showing rapid progression in the characterization of BC
tumors and enhancing novel treatment concepts, the use of next-generational
sequencing technologies hold great promise across many diseases. Here, I will
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review the most well-known subtyping studies into PDAC that extend beyond
identification of previously described aggressive genotypes.
1.L.1. Collisson Subtyping
One of the earliest attempts to define selective PDAC patient populations
based on transcriptional profiling was conducted by Collisson et al.178 This group
premises their work by stating that subsets of tumors and the use of specific
therapies for each has been successful in treating breast and lung cancers, and
the same progress may be achievable in PDAC. Next, they home in on a key issue
with research involving PDAC, namely the availability of patient tumor samples is
grossly lacking. In an insightful moment, the team acknowledges that they can
abrogate the paucity of PDAC samples by using publicly available sequencing data
for tumor samples included in other studies to boost their sample. Using a nonnegative matrix factorization, they established a 62-gene profile that they then
reported identifies three different subtypes (Classical, Quasimesenchymal, and
Exocrine-like) based on their interpretation of known biological roles of associated
genes (Fig 1.13A). Classical PDAC demonstrated high expression of adhesionassociated and epithelial genes. Quasimesenchymal PDAC showed robust
expression of mesenchymal-associated genes. Exocrine-like PDAC had high
expression of digestive enzymes. Further, this study demonstrated significant
differences in survival of patients classified to each of the three subtypes with
Quasimesenchymal PDAC patients having the shortest overall survival and
Classical PDAC patients surviving the longest despite resulting in a near linear
slope (Fig 1.13B). While a noteworthy and well-received conclusion, this study has
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minor oversights that are potentially amplified in the application of its findings. Most
importantly, the samples used for microarrays were not assessed for tumor
composition likely resulting in the general characterization of the three PDAC
subsets. Still, this study serves as an important steppingstone for the study and
expansion of PDAC subtyping and successor studies build on the conclusions
made in this report.
1.L.2. Moffitt Subtyping
The second major attempt to subtype PDAC, by Moffitt et al., made
significant strides to further characterize PDAC gene expression.179 The central
supposition of their attempt laid in the histological observation that the bulk of the
PDAC tumors are comprised of stromal components with few tumor cells. Through
a series of very robust computational methods using microarray data publicly
available for PDAC primary and metastatic tumors, as well as normal pancreatic
tissues, the team was able to virtually microdissect gene expression profiles from
tumor, stromal, and normal compartments of sequenced PDAC samples. These
results, in addition to being a profound achievement, led the researchers to
discover gene expression signatures that greatly expanded the subtypes defined
by Collisson et al. They were able to further separate Collisson’s Classical PDAC
into a second group they called ‘Basal-like’ (Fig 1.14A), the latter of which
demonstrate high expression of basal factors similar to basal positive breast
cancer. Patients with basal-like PDAC tumor also demonstrated significantly
shorter survival, with median life of 11 months following diagnosis compared to 19
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Figure 1.13: Collisson Subtyping of PDAC Tumors

Subtypes of PDAC tumors and cell lines and their prognostic significance. (A) Heat
map of three subtypes of PDAC in DWD-merged UCSF and GSE15471 PDAC
microarray data sets using the PDAssigner gene set. (B) Kaplan-Meier survival
curve comparing survival of individuals with classical (red), QM-PDAC (blue) and
exocrine-like (green) subtypes. P value is by log-rank test.

Used with permission, Collisson, Sadanandam, Olson, et al. Subtypes of Pancreatic Ductal
Adenocarcinoma and Their Differing Responses to Therapy. Nat Med, 2011. 17(4): p. 500-3.
(Appendix A-6)
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months seen in Classical PDAC patients (Fig 1.14B). This study also subdivided
the Collisson Quasimesenchymal into a Normal Stromal Subtype and an Activated
Stromal Subtype. The impactful concept behind this approach is that their virtual
microdissection was able to extrapolate the gene expression profile of the stroma
from the whole tumor sample sequence. This is important because a wealth of
studies have shown that the pathology of in situ tumors involve biological activities
that extend beyond cancer cells involving the surrounding populations of stromal,
immune, and non-cancer cells. Moffitt and group described their activated stromal
subtype having high expression of macrophage-associated genes, as well as
genes attributed to tumor promotion, such as Wnt, matrixins, and fibroblast
activation protein (Fig 1.14C). Patients with Activated Stroma PDAC had a
reduced median survival of 15 months, compared to 24 months in Normal Stroma
PDAC patients (Fig 1.14D). When the various combinations of stromal and tumor
type were merged, an interesting trend in survival was observed (Fig 1.15). Moffitt
and team showed that Classical tumors with Normal Stroma have better survival
than Classical tumors with Activated Stroma; in fact, the former demonstrated the
best survival of all four subtype combinations. However, Basal-like tumors
abrogate any survival benefits ascribed to Normal Stroma. This study substantially
enhanced our ability to demarcate PDAC biology and begin to conceptualize a
personalized approach to therapeutic intervention for patients. Despite the
advances made by this report, few minor shortcomings stand out. Principally, the
whole foundation of the work relies on virtual dissection based on an algorithm to
distinguish normal from disease cells trained using microarray data and
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Figure 1.14: Moffitt PDAC Subtyping Establishes Two Tumor and Two
Stromal Subtypes

Tumor-specific gene expression suggests two subtypes of PDAC tumors. (A)
Consensus-clustered heat map of primary tumors, metastatic tumors, and cell line
models of PDAC generated using correlation, with the underlying distance function
showing two subtypes of PDAC. (B) Kaplan-Meier survival analysis of patients with
resected primary tumors from each tumor subtype in A showing differential
prognosis among the subtypes with a hazard ratio of 1.89 (95% CI = 1.19–3.02, P
= 0.007). The dual action of stroma is described by distinct gene expression
patterns, which are not present in PDAC cell lines. (C) Consensus-clustered heat
map of University of North Carolina (UNC) primary tumor samples, metastases
and cell lines generated using genes from stromal factors. Samples clustered into
three groups, describing samples with activated stroma, samples with normal
stroma and samples with low or absent stromal gene expression. (D) Kaplan-Meier
survival analysis of patients with resected PDAC from the activated and normal
stromal clusters shows that samples in the activated stroma group have worse
prognosis, with a hazard ratio of 1.94 (CI = 1.11–3.37, P = 0.019).

Used with permission, from Moffitt, Marayati, Flate, et al. Virtual Microdissection Identifies Distinct
Tumor- and Stroma-Specific Subtypes of Pancreatic Ductal Adenocarcinoma. Nat Genet, 2015.
47(10): p. 1168-78. (Appendix A-7)
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FIGURE 1.14: MOFFITT PDAC SUBTYPING ESTABLISHES TWO TUMOR
AND TWO STROMAL TYPES
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Figure 1.15: Combining Moffitt Tumor and Stromal Types Demonstrates
Survival Differences

Multivariate survival analysis of tumor and stromal subtypes. (A) Heat map of
tumor samples using 25 genes from each of the tumor and stromal factors, with
samples sorted horizontally by classification. Signature scores for selected gene
sets appear above for each sample. (B) Combined Kaplan-Meier survival analysis
of resected primary tumors from patients with basal-like or classical tumors and
normal or activated stroma showing differential survival (P < 0.001, log-rank test).
Differential prognosis among the subtypes shows complementarity. Classical
tumors with normal stroma (n = 24) had the lowest hazard ratio of 0.39 (95% CI =
0.21–0.73), whereas basal-like tumors with activated stroma (n = 26) had the
highest hazard ratio of 2.28 (95% CI = 1.34–3.87).

Used with permission, Moffitt, Marayati, Flate, et al. Virtual Microdissection Identifies Distinct
Tumor- and Stroma-Specific Subtypes of Pancreatic Ductal Adenocarcinoma. Nat Genet, 2015.
47(10): p. 1168-78. (Appendix A-8)
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FIGURE 1.15: COMBINING MOFFITT TUMOR AND STROMAL TYPES
DEMONSTRATES SURVIVAL DIFFERENCES
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subsequently applied to RNA-Sequence datasets. While not intrinsically
erroneous, this approach does potentially open the door to improperly derived
conclusions, such as the massive difference in sensitivity of the two techniques.
Further, given that non-cancer, tumor-associated tissue surrounding the tumor
cells are attuned to support tumor development, one might question where the
‘zone of most influence’ begins and ends. In other words, how far from the tumor
core does the adapted gene expression profile extend? Despite remaining
questions, this study was the first to make major advances in PDAC subtyping and
created the measure by which future subtyping strategies might be compared.
1.L.3. Bailey Subtyping
While

the

previous subtyping

studies aspired

to

describe

the

characteristics of established PDAC tumors, the next major study sought to define
disease initiation routes by gene expression profile. Bailey et al. began with a huge
cohort of PDAC tumor samples and derived four entirely novel expression-based
subtypes.22 Their approach employed an unsupervised clustering of 96 samples
with greater than 40% tumor content, the results of which were applied to 232
samples. The expression fingerprints were assessed for biological networks to
ascertain their features (Fig 1.16A). The first type was highlighted by involvement
of inflammation, metabolic remodeling, autophagy regulation, EGF signaling, and
the transcription factor Tp63ΔN and its target genes. Bailey and group ascribed
the last group of genes to features of breast, bladder, lung, and head and neck
cancers, since this transcription factor regulates epithelial genes in the absence of
functional Tp53, which led them to term this subtype Squamous PDAC. Next, they
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described a subset that indicated activation of genes attributed to embryological
development of the pancreas, including PDX1, HNF1A/B, HNF4A/G, FOXA2/3,
and HES1. Consequently, they labeled this subtype Pancreatic Progenitor PDAC.
Important to this dissertation, they also described Progenitor tumors as having high
MUC1 and MUC5AC expression, which they also recognized as IPMN-associated
mucins, and which led them to hypothesize that this subtype might arise from IPMN
progression. The third group of tumors was enriched for genes activated during
functional pancreatic differentiation and defined the endocrine and exocrine roles
of pancreatic cell populations, such as digestive enzymes and genes linked to
Maturity-Onset Diabetes of the Young (MODY). Thus, this subtype was labeled
Aberrantly Differentiated Endocrine Exocrine (ADEX). The final gene signature
involved immune cell function pathways, including antigen presentation and TCR
signaling pathways. The group called this final subtype Immunogenic PDAC.
Assessing the impact of these four subtypes on patient survival, Squamous PDAC
demonstrated the worst survival with a median of 13 months with little difference
(30 vs 24 vs 26 months) between the other three subtypes (Fig 1.16B). This study
is commendable in that it attempts to define biological origins and functional
evolution of PDAC tumors and potentially could indicate unique therapies for
successful treatment of patients with each type, aside from the significant impact
this study has in PDAC subtyping, it does rely on microarray data which, as noted
for the previous study, has lower sensitivity than next-generational sequencing.
Given that the researchers highlight key transcriptional factor-activated pathways,
the reduction in sensitivity has the possibility of obscuring lower expressed factors
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Figure 1.16: Bailey PDAC Profiling Establishes Four Subtypes

(A) Molecular classes and transcriptional networks defining PDAC. Unsupervised
analysis of RNA-Seq data identified 4 PDAC classes: squamous (blue); ADEX
(abnormally differentiated endocrine exocrine; brown); pancreatic progenitor
(yellow); and immunogenic (red). *P < 0.05, Fisher’s exact test. (B) Kaplan–Meier
analysis of patient survival stratified by class.

Used with permission, Bailey, Chang, Nones, et al. Genomic Analyses Identify Molecular Subtypes
of Pancreatic Cancer. Nature, 2016. 531(7592): p. 47-52. (Appendix A-9)
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FIGURE 1.16: BAILEY PDAC PROFILING ESTABLISHES FOUR SUBTYPES
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or expression regulators associated with these transcription factors. Additionally,
the presence of endocrine and exocrine expressed genes in the samples is a hotly
contested finding and islet and/or acinar cell contamination of their samples has
been suggested, as Bailey and group used whole tumor for their study. However,
this very recent report had an important role in encouraging the direction of the
original work described in this thesis.
1.L.4. Law Subtyping
While the previous subtyping studies were based on genomic and
transcriptomic profiling, a recent report from Law et al. employed proteomic
technologies to profile the translational repertoire of PDAC tumors.186 While RNAbased profiling has the great potential to implicate biological aberrations within
PDAC tumor cells, proteomic profiling has the added advantage of defining the
active functional signature of disease. Law and team were able to correlate their
findings to the previous three PDAC subtyping reports significantly (Fig 1.17A-F).
By assessing their identified peptides through Gene Ontology enrichment, they
report that they can distinguish Moffitt’s classical, low stromal tumors into two
distinct new subtypes marked by expression of either Metabolic reprogrammed or
progenitor-like subtypes, the latter term was elected due to the similarities with the
Bailey Progenitor-like signature. Law and group continue to describe additional
new subtypes which overlapped with Bailey’s Squamous and Collisson’s
Quasimesenchymal subtypes. However, based on their proteomic discovery, they
further discriminate the Bailey Squamous into two unique subtypes they call
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Figure 1.17: Law et al. Subtyping Derives Four New PDAC Subtypes with
Overlap of Previous Subtyping Studies

(A) Heatmap of samples showing the association between protein expression and
the proteomic subtypes, with proteomic subtypes compared to subtypes from
Moffitt, Collisson, and Bailey strategies. The missing data in the ribbon above the
heatmap indicate the signatures’ scores for these samples did not reach the
threshold to accurately assign a corresponding transcriptomic subtype. The red
and blue colors in each pixel indicate protein up- and downregulation, respectively.
(B) Representative signature gene expressions in the Moffitt et al. classification
scheme across the four proteomic subtypes. The signature scores of the four
proteomics subtypes in the (C) Moffitt et al., (D) Collisson et al., and (E) Bailey et
al. classification systems. Kaplan–Meier survival curves of (F) all patients, (H)
combined proliferative and inflammatory subtypes, and (I) combined metabolic and
progenitor subtypes.

Used with permission, Law, Lagundzin, Clement, et al. The Proteomic Landscape of Pancreatic
Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with
Clinical Response. Clin Cancer Res, 2020. 26(5): p. 1065-76. (Appendix A-10)
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FIGURE 1.17: LAW ET AL. SUBTYPING DERIVES FOUR NEW PDAC
SUBTYPES WITH OVERLAP OF PREVIOUS SUBTYPING STUDIES
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Proliferative and Inflammatory PDAC due to pathway scoring. This report is
notable in that the researchers are able to compare their PDAC subtypes to
therapeutic outcomes (Fig 1.17E-I). While no significant differences were
observed in Proliferative and Inflammatory PDAC patients treated with either
gemcitabine or the combination line FOLFIRINOX (leucovorin, fluorouracil,
irinotecan, and oxaliplatin), patients with Metabolic and Progenitor-like PDAC
demonstrated better response to FOLFIRINOX therapy compared to monotherapy
gemcitabine. This study is inimitable as it steps away from transcriptional analyses
(commonly criticized for failure or difficulty to attribute to the macro-picture of
biological activity in cancers) and goes directly to protein expression. This benefit
comes with the tradeoff of sensitivity. While mass spectroscopy can identify
thousands of peptide sequences with robust expression, RNA sequencing and
microarray platforms can identify tens of thousands of RNA species even at very
low concentrations. Additionally, this study used PDAC tumor samples isolated
from PDAC liver metastases. Therefore, the conclusions of this work must be
limited to the academic scope of disease signatures involving suitability of tumor
and metastatic site adaptations. Even more, the samples used in Law’s work were
whole tumor specimen and hepatic cell contamination cannot be entirely ruled out.
1.M Conceptualization of Dissertation Work
Based on this extensive literature, this dissertation work sought to achieve
five major accomplishments. First, a complete mucin expression profile for PDAC
has never been published despite the indisputable involvement of mucins in PDAC
pathology, initiation, treatment response, and progression. Therefore, it is fitting to
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begin with a complete assessment of mucin transcription using publicly available
PDAC RNA-Sequencing datasets. Next, this dissertation research aspired to
marry the concepts of cancer-associated alternative splicing with mucin
expression, describing the expression and prognostic implications of alternatively
spliced mucin species. Thirdly, because mucins have biological involvement, this
work sought to derive gene expression signatures from unique mucin clusters to
explore the possibility of a novel mucin-based PDAC subtyping strategy. Fourth,
in this research, I selected a significant prognosis-associated mucin splice variant,
and determined its biological function contributing to more aggressive PDAC
disease. And finally, using the sequence of prognostic mucin splice variants, I
aimed to develop a novel diagnostic assay using patient bio-fluids, and to explore
its potential clinical utility.
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Hypotheses and Dissertation Aims
The overall goal of this dissertation is to explore the expression of Mucins
(MUCs) and their alternative splice variants (SVs) in PDAC. Pancreatic cancer
(PC) has a 5-year survival rate of only 10% and is projected to increase in both
incidence and mortality. This grim perspective of PC is likely the consequence of
a multitude of converging factors, including a lack of early symptoms contributing
to late diagnosis, early metastasis, and poor understanding of its pathology. With
no reliable diagnostic or prognostic biomarkers and the lack of actionable targets,
the next significant clinical milestone toward better treatment of PC patients is the
identification of PC-specific biomolecules that can assist in earlier diagnosis and
therapeutic targeting. MUCs have gained significance for their role in PC
progression, diagnostics, and therapeutic targeting. However, their precise
mechanistic contribution is poorly understood.
Based on preliminary studies and published literature, the central
hypotheses of this thesis are 1) MUCs are selectively expressed in PDAC
patients, 2) MUC SVs alter their typical functions in expressing cells and
contribute to pancreatic cancer pathology, and 3) MUC SVs may serve as
unique diagnostic and prognostic markers detectable from patient plasma. I
proposed the following specific aims to address these hypotheses.
Specific Aim I: Surprisingly, a composite dissection of MUCs expressed in human
PDAC patient tumors has not been reported. Further, alternative splicing of PDACassociated MUCs has yet to be evaluated. Due to the abundance of typical and
aberrantly expressed MUCs in PDAC, I hypothesized that mucin profiles might
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highlight a new avenue of PDAC research. Utilizing RNA-sequencing data from
150 PC patients in the TCGA database, total expression of mucins and their
annotated SVs were explored and compared to disease parameters. Additionally,
all known MUCs and MUC SVs were correlated with the survival outcome in TCGA
PDAC patients. Using the TCGA PDAC dataset, I established four clusters of
MUCs and correlated them with activated pathways indicated by specific gene
expression correlated to MUC principal component analysis, identifying four
putative novel PDAC subtypes.
Specific Aim II: Explore the functional consequences of MUC4∆6 in PC
disease pathogenesis.
Examination of the MUC4∆6 sequence revealed that its processing
produces an in-frame deletion of exon 6 interfering with its nidogen-1-like (NIDO)
domain. Further investigation using PCR demonstrated that MUC4∆6 is positively
and exclusively expressed in PC cell lines and patient surgical resection samples.
Previous studies from our group have investigated the pathological implications of
MUC4 SVs lacking tandem repeat domains in MUC4/X and MUC4/Y and the
importance of MUC4 NIDO domain in metastasis of PC. However, the functional
relevance of MUC4∆6 in the presence of wild-type MUC4 in PDAC has not been
studied. I hypothesized that MUC4∆6 cooperates with wild-type MUC4 to promote
invasion and migration of PDAC cells. Given that expression of MUC4∆6
corresponds to poor survival time in PC patients and loss of exon 6, which
corresponds to the NIDO domain and confers stromal interaction functionality,
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plausibly it induces altered or neofunctionality in the presence of wild-type MUC4.
Therefore, I generated an overexpression vector and transfected it into PDAC cell
lines having intrinsic MUC4 expression to explore the functional effects of MUC4∆6
expression. I planned to compare the in vitro differences in cell proliferation,
viability, and invasion and in vivo tumorigenesis and metastasis in a mouse model.
Specific Aim III: Validate the detection of mucin SV in patient plasma while
confirming their specificity for PC.
I hypothesized that PC-specific, alternatively spliced and mutated gene
transcripts can be detected in patient plasma and that my predicted MUC4Δ6 SV
from Aim I is a unique marker of PDAC. Therefore, I developed gold nanoparticles
covalently linked to short sequence-specific oligoprobes with conditional
fluorescence requiring target hybridization and enzymatic cleavage for signal
activation. My nanoparticle assay overcomes the hurdles of specificity of
antibodies, spatiotemporal expression, stability of protein of interest, and ease of
multiplexing. Since the action of DNA duplex-specific nuclease requires precise
basepair complementarity, my nanoprobe assay can serve as a plasma-based
method to detect numerous spliced and mutated transcripts. Based on the
prognostically significant MUC4Δ6 from my analysis of TCGA patient data, I
demonstrated using in vitro methods that this transcript is: 1) detectable in patient
plasma and 2) specific to PC in a disease stage-independent manner. I tested my
novel nano-probe assay using samples from our lab’s extensive library of patient
plasma samples derived from malignant, benign, and nonpathological conditions,
detecting the MUC4Δ6 RNA in circulating RNA using my novel assay. In addition
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to MUC4Δ6 probes, I demonstrated using specific probes that I can also detect
PC-specific and constitutively active KRASG12D.
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DUCTAL ADENOCARCINOMA
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2.A Introduction
Here, I present a focused bioinformatics-based strategy using PDAC RNASeq data from TCGA (gdc.cancer.gov

142)

for the expression of mucin genes and

SVs. I investigated the importance of assessing the cellularity of PDAC tumor
samples when analyzing transcriptomic data and demonstrated a quantitative
strategy to correct mucin expression based on malignant cellularity. I utilized the
extensive expression of mucins to explore correlations between specific mucin
genes. These correlations were used to identify four mucin-based subtypes and
explore the possible biological processes activated within each specific PDAC
subtype. Finally, I assessed the expression of all 107 known mucin SVs and the
impact of their expression on the overall survival outcome. I validated the
expression and survival association of two opposing SVs. Taken together, our
analyses suggest that selective expression of mucins may have novel implications
in PDAC tumor biology, and certain SVs may contribute to disease parameters,
impact the survival of PDAC patients, and serve as excellent diagnostic and
prognostic markers. Clinical advances in next-generation profiling to identify novel
therapeutic targets or diagnostic biomarkers in PC lags behind other malignancies
while treatment outcomes remain unimproved. This disparity in therapeutic
response is partly due to numerous physical characteristics of PC tumors,
including exacerbated desmoplastic reaction
therapeutic resistance

27, 151, 162,

25, 26,

poor drug perfusion

26,

innate

and further complicated by the majority of

diagnoses being made in late-stage disease.21 We and others have demonstrated
that PC tumors aberrantly express abundant mucins
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31-33, 128, 132, 161, 187, 188
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generate a large number of alternatively spliced isoforms

129, 137-141, 188, 189.

Experiments on many mucin-associated domains have provided limited evidence
for functional interactions. Though molecular studies have revealed several
consequential alterations in PC, like the expression of constitutively active KRAS
mutant, loss of cell cycle checkpoint inhibitors, and aberrant mucin expression, the
complete story remains obscured. I believe that the results of this project address
the shortcomings in available scientific knowledge, including: 1) if PC tumors
express isoforms specific to the disease setting, 2) detectability of diseaseassociated splice variants from biofluids, 3) the prognostic implication of
alternatively spliced genes in the course of disease progression, and 4) functional
consequences of alternatively spliced genes.
2.B Results
2.B.1. General outline of patient samples
The pancreatic cancer dataset (PAAD) in TCGA contains a total of 182
patient samples. Of those, 8 were later confirmed neuroendocrine, 24 were other
diagnoses (acinar carcinoma, unknown origin, etc.), and 150 were histologically
confirmed PDAC (Fig 2.1A). Of those 150 PDAC, all had cellularity scores and
applicable clinical history except one. Almost 83% of those 149 samples were
diagnoses between the ages of 50-80 years (Fig 2.1B) and over half were male
(Fig 2.1C). Comparing the histological stage, approximately 50% were Grade 2,
46% were Grade 3, while 5 were Grade 1 and a single samples was Grade 4 (Fig
2.1D).
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Figure 2.1: TCGA PDAC Patient Demographics

Patients in the Pancreatic Cancer Dataset (PAAD) of TCGA are associated with a
variety of demographic and clinical paraments. (A) The majority of patients were
between the ages of 50-80 years old at the time of diagnosis. (B) Of the 182 total
cases, only 150 were confirmed PDAC after submission and upload. This
population was selected for analyses. (C) Just over half the PDAC cases were
male despite no apparent increased sex-based risk of developing PDAC in
literature. (D) Out of the 150 total PDAC cases, 149 cases had tumor sample purity
scores reported. Around half of these cases were Grades 2 and 3.
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FIGURE 2.1: TCGA PDAC PATIENT DEMOGRAPHICS

104

2.B.2. Mucins expression influenced by malignant cellularity
Characterization of patients’ samples in TCGA dataset revealed robust
expression of the epithelial marker CK19 in high cellularity samples (determined
by individual ABSOLUTE Purity scores above the median of all samples reported
by the TCGA Consortium on the PAAD dataset). However, samples demonstrated
a wide variation in amylase expression, with high cellularity expressing 0-23787
transcript per million (TPM, median= 3.3 TPM) and 0 to 41320 TPM (median= 41.4
TPM) in low cellularity. (Fig 2.2). Low expression of CD45 and leptin in both high
and low cellularity groups indicated low immune and adipocyte populations.
Mesothelin expression was unsurprisingly substantial, with a median expression
of 326.9 TPM and 132.8 TPM in high and low cellularity, respectively.
Mucin expression was compared between high cellularity (n=74) and low
cellularity samples (n=75) to healthy tissues or between high and low cellularity
samples (Fig 2.3). All cases demonstrated a wide range of mucin expression
between patients with substantial differences in high and low cellularity groups.
Four groups of mucins were established using Pearson’s correlation and five
clusters of patients generated by Spearman correlation dendrograms of logtransformed mucin expression values. MUC19 clustered alone (group 1),
MUC1/3/12/13/17/20

(group

2),

MUC6/15/22

(group

3),

and

MUC2/4/5AC/5B/16/21 (group 4). Survival analysis of the high cellularity patients
based on patient clustering of this mucin expression demonstrated significant
differences in overall survival (Fig 2.3B, Wilcoxon p=0.05). Cluster 5 patients
demonstrated the highest expression of group 2 mucins and had the longest
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Figure 2.2: Cellular Composition of TCGA PDAC Samples

Samples from the dataset indicate high expression of ductal marker keratin-19
(CK19) and stromal component mesothelin (MSLN). Significant differences are
observed between high and low tumor purity samples for all genes except acinarassociated amylase (AMY2A). Boxplots were given by log-transformed TPM
expression. Significance results are from the student’s t-test.
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FIGURE 2.2: CELLULAR COMPOSITION OF TCGA PDAC SAMPLES
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Figure 2.3: Expression of Mucins in the TCGA PDAC Dataset

Expression of mucins in the TCGA PDAC dataset before cellularity correction of
the samples shows significant survival differences between the patient of different
mucin signatures. (A) Heatmap and boxplots of cellularity-uncorrected expression
of all mucins in the combined patient population or stratifying patient samples by
malignant cellularity into high (n=74) or low (n=75) cellularity. Four groups of mucin
expression profiles were established by correlation dendrogram comprised of
MUC19 alone (group 1), MUC1/3/12/13/17/20 (group 2), MUC6/15/22 (group 3),
and MUC2/4/5AC/5B/16/21 (group 4), and patients were stratified into five clusters.
(B) Kaplan-Meier survival plots of the high cellularity subjects in the five clusters
demonstrated a statistically significant difference in early deaths (Wilcoxon pvalue=0.05) between the groups with cluster 3 (high group 3 mucins, especially
MUC15, and high MUC5B expression) having the worst median overall survival
(308 days); cluster 4 demonstrating a median survival time of 394 days; cluster 1
median survival was 460 days; cluster 2 median survival was 545 days; and cluster
5 (highest expression of group 2 mucins) having the longest median survival time
(732 days). Significance results are from Wilcoxon test between High and Low
Cellularity groups. Mucins were clustered in 4 groups by Pearson correlation
dendrogram into 5 clusters of patients by Spearman correlation. All boxplots were
given by log-transformed TPM expression. Significance indicated by: *= ≤0.05 and
**= ≤0.005.
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FIGURE 2.3: EXPRESSION OF MUCINS IN THE TCGA PDAC DATASET
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median survival of 732 days compared to the worst surviving patients (median of
308 days) in cluster 3, which had high group 3 mucins (especially MUC15) and
high MUC5B expression.
Further, I assessed the clustering of mucin expression and their
association with overall survival in PDAC patients using a secondary RNA-Seq
dataset (PACA-AU) 190 from the International Cancer Genome Consortium (ICGC)
191,

and confirmed harmonization in the mucin groups identified between both

datasets. In this dataset, the four mucin clusters (Fig 2.4A) were comprised of
MUC12/22 (group 1), MUC4/15/16/21 (group 2), MUC3A/6/19 (group 3), and
MUC1/2/5AC/5B/13/17/20 (group 4). Comparing this dataset to cellularity
uncorrected TCGA samples, two groups of mucins showed substantial synchrony.
Group 2 mucins of ICGC overlapped TCGA group 4 by MUC4/16/21, and ICGC
group 4 was similar to TCGA group 2 with MUC1/13/17/20. Interestingly, although
the patient cohort in this dataset clinically resembled TCGA patients, mucin
expression was lower than that observed from TCGA. The ICGC patients were
clustered by Spearman’s correlations into 5 distinct clusters. Accessing overall
survival outcomes in these clusters resulted in significantly different (p=0.02) loss
of life (Fig 2.4B). Clusters 4 and 5 had the worst survival with medians of 388 and
361 days, respectively. Cluster 4 patients demonstrated high expression of group
2 mucins while cluster 5 patients had higher group 3 mucins. Both had low group
4 mucin expression. Clusters 1 and 2 both demonstrated similar mucin signatures,
including high expression of group 4 mucins, with the exception that cluster 1 also
displayed high group 2 expression. The differences in survival were substantial,
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Figure 2.4. Expression of Mucins in the ICGC PDAC Comparison Dataset and
Survival Associations

Expression and clustering of mucins in the ICGC PACA-AU PDAC dataset
demonstrated significant survival differences between mucin signature clusters.
(A) Four groups of mucins were identified by Pearson correlation using scaled
expression and five clusters of patients sorted using Spearman’s correlation of
mucin expression. Mucin groups were comprised of MUC12/22 (group 1),
MUC4/15/16/21 (group 2), MUC3A/6/19 (group 3), and MUC1/2/5AC/5B/13/17/20
(group 4). (B) Overall survival in the five patient clusters resulted in significantly
different outcomes (Log Rank p=0.02). Clusters 4 and 5 had the worst survival with
medians of 388 and 361 days, respectively. Clusters 4 patients demonstrated high
expression of group 2 mucins while cluster 5 patients had higher group 3 mucins.
Both had low group 4 mucin expression. Clusters 1 and 2 both demonstrated
similar mucin signatures, including high expression of group 4 mucins, with the
exception that group 1 also displayed high group 2 expression. The differences in
survival were substantial, with cluster 1 patients having a median overall survival
of 709 days compared to 1144 days in cluster 2 patients.

111

Chapter II: Mucin Expression Profiling

FIGURE 2.4: EXPRESSION OF MUCINS IN THE ICGC PDAC COMPARISON
DATASET AND SURVIVAL ASSOCIATIONS
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with cluster 1 patients having a median overall survival of 709 days compared to
1144 days for cluster 2 patients. The expression of MUC4/16 is likely an important
factor underlying this discrepancy. Cluster 3 patients displayed lower mucin
expression and had a median survival of 768 days.
The malignant cellularity-corrected expression of mucins significantly
adjusted all observed medians (Table1), and four groups of mucin genes in five
clusters of patients were identified by standardized correlation heatmap
visualization (Fig 2.5A). The mucins sorted into MUC7/12/17 (group 1),
MUC1/3/13/19/20 (group 2), MUC6/15/22 (group 3), and MUC2/4/5AC/5B/16/21
(group 4). The overall survival of these five cellularity-corrected clusters of patients
(Fig 2.5B) demonstrated a significant difference in early deaths (Wilcoxon p=
0.03). Cluster 1 patients appeared to have lower expression of group 2 mucins and
strong expression of group 4 mucins (especially MUC16), and the shortest median
survival of 293 days. Cluster 2 patients, however, had the longest overall survival
of 1059 days, demonstrating higher group 2 mucin expression (particularly MUC1).
Clusters 3 and 4 had similar median survival times (598 and 593 days,
respectively), with the former demonstrating low group 2 mucin expression but high
MUC4 expression and the later exhibiting higher group 2 and group 1 mucin
expression. Cluster 5 patient median survival was 738 days and demonstrated a
high MUC5AC expression but also higher group 2 mucins (especially MUC13).
Assessing individual mucins, MUC1 expression was highest before and after the
cellularity correction. The expression of MUC2/7/19/21/22 was minimal with
uncorrected and corrected medians below 1 TPM. The MUC13 demonstrated the
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TABLE 1: MEDIAN MUCIN EXPRESSION BETWEEN STRATIFIED TCGA
PDAC AND ICGC SAMPLES.

Median expression of all mucins between adjacent normal and PC samples was calculated in the
combined patient population and stratified by cellularity in the TCGA dataset and compared to
median expression observed in the ICGC dataset. Values reported after TPM normalization.

Figure 2.5: Cellularity-Correct Expression of Mucins in TCGA Generates Four
Novel Clusters

Expression and clustering of mucins in the TCGA PDAC dataset after cellularity
correction of the samples. (A) Heatmap of cellularity-corrected expression of all
mucins and expression boxplots of the combined patient population and after
stratifying patient samples by malignant cellularity into high (n=74) or low (n=75)
cellularity. Mucin expression correlations resulted in four new profiles comprised
of MUC7/12/17 (group 1), MUC1/3/13/19/20 (group 2), MUC6/15/22 (group 3), and
MUC2/4/5AC/5B/16/21 (group 4). (B) Kaplan-Meier survival plots of the 5 subject
clusters demonstrated a statistically significant difference in early deaths
(Wilcoxon p-value=0.0346) between the groups with cluster 1 (lower expression of
group 2 mucins and strong group 4 expression, especially MUC16) having the
worst median overall survival (293 days); cluster 3 (low group 2 expression and
higher MUC4 expression) and cluster 4 (high groups 1 and 2 mucins) having
similar median survival times (598 and 593 days, respectively); cluster 5 (high
MUC5AC and group 2 expression, especially MUC13) having a median survival
time of 738 days; and cluster 2 (high group 2 mucin expression, particular MUC1)
having the longest overall survival (1059 days). Significance results are from
Wilcoxon test between High and Low Cellularity groups. Mucins were clustered in
4 groups by Pearson correlation dendrogram into 5 clusters of patients by
Spearman correlation. All boxplots were given by log-transformed TPM
expression. Significance indicated by: *= ≤0.05 and **= ≤0.005.
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FIGURE 2.5: CELLULARITY-CORRECT EXPRESSION OF MUCINS IN TCGA
GENERATES FOUR NOVEL CLUSTERS
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second highest expression level, which significantly increased after cellularitycorrection. Among some mucins, cellularity correction reversed the trends in
expression. For instance, MUC4 expressed higher in the high cellularity; however,
after correction, low cellularity demonstrated the highest expression, suggesting
that the malignant cells with higher stromal contents may express more copies of
MUC4 compared to the former. However, the higher expression of MUC5AC in
high cellularity cases was reaffirmed after cellularity-correction, possibly due to a
paracrine- or autocrine-mediated forward signal. I concluded from these analyses
that a qualitative stratification strategy would fail to provide an accurate
comparison of samples with different cellularity scores within the same strata.
Thus, I elected to proceed with the cellularity-corrected mucin expression levels
for future analysis.
2.B.3. Mucin-dependent PDAC patient subtyping
Principal component analysis (PCA) of mucin expression using Spearman
correlations elucidated mucin signatures of PDAC. The PCA of uncorrected TCGA
mucin expression was compared to PCA of ICGC samples. Using the cutoff values
explained in the methods section, both datasets resulted in three significant PCs
with substantial overlap in dominant mucins contributing to the groups (Fig 2.6AE). After confirming significant overlap between the two datasets, I proceeded to
PCA calculations using malignant cellularity corrected TCGA mucin expression.
The PCA resulted in four significant principal components (PC), determined using
p≤0.05 and eigenvalues ≥1, which explained nearly 70% of the variation in
expression. The heaviest loading mucins from each of the four PCs were
117
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Figure 2.6: PCA Clusters of Mucins in TCGA and ICGC Overlap

PCA clustering of mucins overlaps between TCGA and ICGC and suggests mucin
signature subtypes are linked to activation of unique pathways. After calculating
independent PCAs of mucin expression in the cellularity-uncorrected TCGA and
ICGC datasets, the heaviest loading mucins to each principal component were
compared. (A) In PC1, all mucins observed in the TCGA dataset were also part of
PC1 from ICGC with the addition of MUC6 in the latter. (B) PC2 in both sets
contained the heaviest loads from MUC4, MUC16, and MUC20. ICGC PC2 also
included a positive contribution from MUC12 and negative contribution from
MUC6, while TCGA PC2 variation was additionally explained by positive
contribution from MUC5B and negative contributions from MUC3 and MUC17. (C)
Variation in PC3 from both datasets was mostly contributed from positive loads
from MUC12 and negative contributions from MUC5B and MUC6. TCGA PC3
variation was additionally explained by positive loading from MUC4 and MUC16,
while ICGC PC3 variation was further explained by positive contributions from
MUC13 and MUC17 and negative load from MUC5AC. (D) Scree plot of PCA on
TCGA PDAC cellularity-uncorrected mucin expression shows 3 significant PCs.
(E) Scree plot of PCA on ICGC PACA-AU PDAC mucin expression shows 3
significant PCs. (F) From the significant principal components, the top four
identified unique MUC expression patterns, summarized within the table, and their
load and contribution to the PC.
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FIGURE 2.6: PCA CLUSTERS OF MUCINS IN TCGA AND ICGC OVERLAP
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summarized into distinct panels (Fig 2.6F). I selected mucins with load values
>|0.5| in principal component 1 (PC1) and >|0.3| for all others. The PC1
demonstrated the complex association of gene expression comprised of positive
contributions from MUC1/3/5B/12/13/17/20. The PC2 was comprised of positive
association by MUC4/5B/16 and negatively from MUC3/17. The PC3
encompassed positively from the expression of MUC5AC/5B/6 and negatively
from MUC4/12. The PC4 was composed of positive expression of MUC5AC and
negatively for MUC6 expression.
I calculated the Spearman correlations of all genes to each of the four PC’s
relative to their medians and considered genes that had significant Bonferronicorrected p-values for all correlation groups followed by Ingenuity Pathway
Analysis for four positively correlated lists of genes (Fig 2.7). An immune response
signature is the most implicated feature in PC1. Based on this finding, I analyzed
the expression of CD45 in PC1 patients and found a high expression of CD45 in
high PC1 compared to low PC1 (13.9 TPM vs. 7.2 TPM, p=0.0113). Pathways
analysis of PC2 correlated genes indicated signaling through glucocorticoid
receptors, vitamin D, and epithelial-mesenchymal transition (EMT) regulation.
Studies have suggested that glucocorticoids can induce EMT, therapy resistance
and enhance metastasis in PDAC

192;

therefore, considering the well-known role

of EMT in cancer biology, I designated the PC2 cohort of tumors as progressing
and aggressive. The PC3-associated pathways revealed activation of the SPINK1,
maturity-onset diabetes of young (MODY), and acute phase response pathways
suggesting high acinar involvement and stress-induced responses within the
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Figure 2.7: Mucin Signatures Demarcate Unique Pathway Activations

PCA clustering of mucins overlaps between TCGA and ICGC and suggests mucin
signature subtypes are linked to activation of unique pathways. The positively
correlated genes from the entire transcriptome to each PC were fed into pathway
analysis software to explore the pathways affected. PC significance was
determined using Bartlett’s test ≤0.05 and eigenvalues ≥1. Loading thresholds
were set to absolute values of 0.5 for PC1 and 0.3 for all other PCs.
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FIGURE 2.7: MUCIN SIGNATURES DEMARCATE UNIQUE PATHWAY
ACTIVATIONS
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tumor. Therefore, I hypothesize that the PC3 associate with a gene signature
involving acinar insult or chronic pancreatitis/inflammation. Supporting this
assumption, amylase expression in high PC3 patients had a median of 53.5 TPM,
and a median of 1.02 TPM (p=0.0306) in low PC3, indicating the significant
contribution by acinar cells in the high PC3 patient samples. Many processes
correlated with PC4-associated genes imply a downregulation of inflammation, as
suggested by the upregulation of melatonin, nicotine, and serotonin degradation.
Interestingly, an upregulation of signaling through the c-MET family receptor
tyrosine kinase Recepteur d’Origine Nantais (RON) via its ligand Macrophage
Stimulating Protein (MSP) suggests a potential route of tumorigenesis through
intraepithelial neoplasia (PanINs) progression 193 to PDAC for PC4. Further, naïve
Bayes calculations resulted in highly accurate prediction of patients to an Immune
Activated/Low Cellularity Tumors (PC1) with an area under the curve (AUC) of
0.9648 (Fig 2.8A) as well as Progressive/Aggressive Transforming Tumors (PC2)
with an AUC of 0.9971 (Fig 2.8C). Predictions were slightly less powerful, although
still high for Pancreatitis/Acinar Initiated Tumors (PC3) with an AUC of 0.8833
(Fig2.8B) and Anti-Inflammatory/PanIn Initiated Tumors (PC4) with an AUC of
0.8529 (Fig 2.8D). Seeking to explore the impact of mucin-based PDAC subtypes
on survival outcome, the TCGA samples were stratified into groups based on their
PC score relative to the median, comparing the top 25% (high PC) to the bottom
25% (low PC). Overall median survival outcome was statistically significant for PC1
(p=0.04), with higher PC surviving longer than lower PC (738 vs. 511 days, Fig
2.8E). Survival curves of High and Low PC4 patients indicated a trend toward
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Figure 2.8: PCA-Significant Mucins Independently Predict Association to
MUC-Based Subtypes

Using the heaviest weighted mucins from the PCA, mucin panels were established
and used to predict patient PDAC tumor subtype. (A) Using the cellularitycorrected expression of MUC1/3/5B/12/13/17/20, we were able to accurately
predict patients as having immune activated tumors (PC1) with an AUC 0.9648.
(B) The cellularity-corrected expression of MUC3/4/5B/16/17 most accurately
predicted patient tumors to a progressive/increasing aggressiveness subtype
(PC2) with an AUC of 0.9971. (C) The cellularity-corrected expression of
MUC4/5AC/5B/6/12 predicted patients to be in the pancreatitis/acinar cell damage
induced subtype (PC3) with an AUC of 0.8833. (D) Cellularity-corrected
MUC5AC/6 could predict patient tumor subtype anti-inflammatory (PC4) with an
AUC of 8529. (E) Comparing survival in the top 25% to the bottom 25% of immune
activation subtype (PC1) highlighted a significant difference in overall survival, with
high PC1 patients surviving 227 days longer on average (p=0.0497). (F)
Comparing the survival of the top 25% to the bottom 25% of anti-inflammatory
subtype (PC4), an appreciable trend is observable, with patients having low PC4
scores surviving an average of 172 days longer (p=0.2018).
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FIGURE 2.8: PCA-SIGNIFICANT MUCINS INDEPENDENTLY PREDICT
ASSOCIATION TO MUC-BASED SUBTYPES
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Figure 2.9: Mucin Splice Variants Correlate with Differential Survival
Outcome in PDAC Patients

Survival plots based on expression above (High Expression) or below (Low/No
Expression) the non-zero median of the 9 highest expressed mucin SVs
significantly correlated with survival outcome. (A) High expression of four MUC1
and one MUC13 SVs were associated with better survival. (B) Boxplots of these
five SVs associated with better survival demonstrate that MUC13-sv-205 has the
highest expression, followed by MUC1-sv-222, with the other three MUC1 SVs
expressed at similar lower levels. (C) Higher expression of both MUC4, MUC15,
MUC16 SVs were associated with worse survival. (D) Boxplots of these four SVs
associated with worse survival demonstrate that both MUC4, MUC15, MUC16 SVs
expressed at similar levels with MUC16-sv-201 expressed slightly higher.
Expression of significant SVs given in log transformed TPM.
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FIGURE 2.9: MUCIN SPLICE VARIANTS CORRELATE WITH DIFFERENTIAL
SURVIVAL OUTCOME IN PDAC PATIENTS
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worse survival in high PC4 patients with an average survival time of 632 days
compared to 804 days in low PC4 patients (p=0.2018, Fig 2.8F).
2.B.4. Identification of mucin splice variants associated with PDAC survival
The discordance of individual mucin expression associating with expected
patient survival in TCGA samples, either with cellularity-uncorrected or cellularitycorrected values, led me to consider the expression of alternatively spliced mucins.
Therefore, I realigned the raw RNA-Seq reads from TCGA patients to the current
Ensembl annotations for all mucin transcripts. I generated survival plots for all
mucin transcripts (n=110), excluding those expressed by less than 10 subjects
(n=13), and calculated log-rank and Wilcoxon significance tests. I observed 12
variants associated with survival differences with higher expression of 5 SVs
associated with better survival (Fig 2.9A) and higher expression of 4 SVs
associated with worse survival (Fig 2.9C). Higher expression of four MUC1
transcripts was associated with statistically significant better survival (SV-210: 695
vs. 473 days, p=0.013; SV-221: 695 vs. 532 days, p=0.038; SV-222: 732 vs. 498
days, p=0.022; SV-226: 695 vs. 598 days, p=0.034), with MUC1-SV-210, -221,
and -226 showing significant survival differences in early deaths (respective
Wilcoxon p-value reported). Additionally, better survival outcome was observed in
patients with higher expression of full-length MUC13 (SV-205: 695 vs. 498 days,
p=0.015) and lower risk of early death in higher expression of MUC20 (SV-208:
691 vs. 593 days, p=0.044). Significant risk of earlier death was observed in
patients with high expression of two MUC4 variants (SV-215: 593 vs. 634 days,
p=0.043; SV-220: 460 vs. 652 days, p=0.034) and full-length MUC16 transcript
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(SV-201: 593 vs. 652 days, p=0.031). Additionally, higher expression of two other
mucin transcripts was significantly associated with worse survival, MUC15 (SV203: 486 vs. 684 days, p=0.030) and MUC21 (SV-201: 518 vs. 691 days, p=0.044),
and a higher risk of early death in patients with higher expression of MUC22 (SV201: 607 vs. 614 days, p=0.04). I assessed the expression level of these 12
transcripts (9 of which were robustly expressed across patients) (better survival
SVs Fig 2.9B; worse survival SVs Fig 2.9D) and saw that nearly all subjects
expressed the four MUC1 transcripts (75th quantile: SV-210=2.2 TPM; SV221=5.13 TPM; SV-222=44.28 TPM; and SV-226=8.32 TPM). Just over 70% of
patients expressed MUC4-SV-215 (75th quantile=1.54 TPM) and over 40%
expressed MUC4-SV-220 (75th quantile=0.89). All patients expressed MUC13-SV205 (median=337.1 TPM) and MUC20-SV-208 (median=9.07 TPM). All but one
patient expressed MUC16-SV-201 (median=2.66 TPM). Over 67% of patient
samples demonstrated expression of MUC15-SV-203 (75th quantile=1.63), while
almost 81% had low expression of MUC21-SV-201 (75th quantile=1.04 TPM).
2.B.5. Determining PDAC Tumor Cellularity with PCR
Evaluation of tumor cellularity for samples stored on the Genomic Data
Commons site of TCGA is assessed using the reported tumor purity score
ascertained by the ABSOLUTE Purity Algorithm. However, analysis of gene
expression in validation samples using PCR or simple transcriptomic sequencing
required the innovative design of an alternative technique. By correlating all
transcriptomic data available for all TCGA patients with the cellularity score of each
respective sample, a list of genes highly associated with tumor purity was
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calculated. The top 20 genes were plotted with their R2 LogWorth and p-values
(Fig 2.10A). The top gene hit was epithelial splicing regulatory factor 2 (ESRP2).
However, in silico validation of this single gene lacked the appropriate level of
correlation. Therefore, the top two genes were selected: ESRP2 and protein
tyrosine kinase 6 (PTK6). The combination of both genes greatly strengthened the
predictability of sample cellularity. Because these genes were to be assessed in
PCR, the top negatively correlated gene, melanoma associated antigen H1
(MAGEH1), was also selected for screening. The advantage of use MAGEH1 in
PCR validation of PDAC tumor sample cellularity was that it confirmed successful
gene detection and counterweighted the detection of the positively associated
genes. The cellularity of samples was qualitatively determined by taking the ratio
of MAGEH1 to the average of ESRP2 and PTK6. Using a threshold of 1, high
calculated samples were retained as ‘High Cellularity’ while low samples were
excluded as ‘Low Cellularity’ (Fig 2.10B).
2.B.6. Experimental validation of MUC13 and MUC4∆6 SV
I focused on two SV, one with negative impacts on survival (MUC4-SV215), and one with a positive association with better overall survival (MUC13-SV203), for the experimental validation. The MUC4-SV-215 demonstrated in-frame
skipping of exon 6 (MUC4∆6), which corresponds to the initial portion of the NIDO
domain. MUC13-SV-203 codes for the full-length protein (MUC13WT). I pursued
validation of MUC4∆6 and MUC13WT in a separate patient tumor sample set
obtained from Whipple resections from the UNMC Tissue Sciences Core Facility
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Figure 2.10: Genes Panel for PCR-based Cellularity Assessment

(A) Correlation of transcriptomes to sample cellularity was conducted and the top
20 most significant genes plotted by correlation LogWorth and p-value after false
discovery rate (FDR) correction. ESRP2 and PTK6 were selected as the positively
correlated genes and MAGEH1 was selected as the negative correlation gene. (B)
Thresholding patient samples with the 3 gene panel demonstrated 3 samples were
Low Cellularity while 15 were High Cellularity.
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FIGURE 2.10: GENES PANEL FOR PCR-BASED CELLULARITY
ASSESSMENT
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Figure 2.11: Validation of the expression of MUC13-sv205 and MUC4-sv215

In a separate patient tumor set (n=17) by ddPCR: (A) Of 26 candidate genes, three
had the largest Spearman’s rho: two positively correlated, ESRP2 (rho= 0.6191,
p≤0.001) and PTK6 (rho=0.7682, p≤0.001), and one negatively correlated,
MAGEH1 (rho=-0.6570, p≤0.001). Based on the established use of CK19 as an
epithelial marker, we included it in this analysis to compare its correlation to the
other three (rho=0.4782, p≤0.001). (B) We used the ratio of the average of PTK6
(median expression= 22.8 copies/1000 GPI copies (c/rc)) and ESRP2 (median
expression= 73.4 c/rc) to MAGEH1 (median expression= 19.1) expression. Each
line and color correspond to a single patient. (C) Expression of GPI normalized
MUC13 yielded a median of 56.1 c/rc. (D) Expression of GPI normalized MUC4WT
(median expression= 31.6 c/rc) and MUC4Δ6 (median expression= 51.4 c/rc).
Individual patient samples were plotted to appreciate the difference between both
transcripts (lines and colors indicate the patient labels). Interestingly, all cases
demonstrated higher expression of MUC4Δ6 than MUC4WT except for patients 2
and 6. (E) Stratifying the expression of MUC13WT above (n=8) or below (n=7) the
median, higher expression trended toward better survival (758 vs. 445 days;
p=0.1048). (F) MUC4Δ6 above (n=7) or below (n=8) the median, higher expression
was associated with worse survival (393 vs. 801 days, p=0.0375).
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FIGURE 2.11: VALIDATION OF THE EXPRESSION OF MUC13-SV205 AND
MUC4-SV215
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(n=17) by copy number analysis (CNA; digital PCR). To assess genes associated
with cellularity, the transcriptome was correlated with the ABSOLUTE purity score.
The top two positively correlated and the top negatively correlated genes, in
addition to the canonical keratin-19, were selected for assessment in the validation
set (Fig 2.11A). The malignant proportions of tumor samples were calculated
based on the median expression of PTK6 (7.7 in the low cellularity and 22.8
copies/1000 copies GPI in the high cellularity), ESRP2 (29.4 in low cellularity and
94.8 copies/1000 copies GPI in high cellularity), and MAGEH1 (46.2 in the low
cellularity and 24.7 copies/1000 copies GPI in the high cellularity) (Fig 2.11B). The
sample cellularities were calculated and stratified into high (n=15) and low (n=2).
Overall, expression of MUC13WT, MUC4∆6, and MUC4WT was higher in the high
vs. low cellularity. Comparing the high to low cellularity groups, the median
expression of MUC13WT was 56.1 to 16.9 (Fig 2.11C), MUC4∆6 was 49.1 to 13.2,
and MUC4WT was 23.2 to 6.3 copies/1000copies of GPI (Fig 2.11D). Due to a
lack of a reliable cellularity normalization calculation in our CNA, the low cellularity
samples were excluded from subsequent survival statistical analyses.
Patients were stratified about the median expression of MUC13WT and
MUC4∆6 into high (n=8 and 7, respectively) or low expressers (n=7 and 8,
respectively), and Kaplan-Meier survival curves were plotted. Despite the low
number of available samples, an appreciable trend in survival difference was
observed in both SVs, which supported our in-silico findings. The overall median
survival time was 451 days, but the difference was exaggerated when considering
the stratification components. High expressers of MUC13 had a median survival
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time of 758 days, whereas low expressers had a median survival of 445 days
(p=0.1048, Fig 2.11E). High Expressers of MUC4∆6 had a median survival time of
393 days compared to 801 days in the low expressers (p=0.0375, Fig 2.11F).
2.C Discussion
The expression and function of several mucins have been investigated
within the context of PDAC; however, the scope of these studies is generally
limited to single mucin. The establishment of cancer transcriptome databases has
increased our ability to assess the potential role of previously unrecognized genes
and their variants in specific malignancies. Other studies have reported employing
widely used databases to conclude that the expression of MUC4, especially when
combined with MUC16 and MUC20, was significantly associated with worse
survival outcomes in PC patients

194.

Until present, no study has addressed the

need for cellularity-based correction of the RNA-Seq dataset due to the variable
and often a low number of malignant cells present in PDAC tissues

195, 196.

This

seemingly innocuous oversight obscures the real effects of genes expressed by
cancer cells within PDAC tumors. Furthermore, albeit more detrimental, is the
indiscriminate use of databases that fail to control for or stratify reported cases
adequately. Here I ensured that PDAC samples were correctly vetted before
selection. The difference in survival outcome in pancreatic cancer is intrinsic to the
type, with PDAC have significantly worse survival. Indiscriminate stratification of
TCGA samples by mucin expression essentially separates neuroendocrine tumors
from PDAC, which the former having substantially better survival.
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The concern of malignant cellularity was addressed by the TCGA
Consortium, which used a computational algorithm (ABSOLUTE Scoring) to
quantitatively determine the cancer cell population of tumor samples based on
gene expression and chromatin methylation states

142.

Based on these scores,

they assigned qualitative cellularity labels (high or low cellularity) to each sample.
This method, while resourceful, poses a statistical dilemma. While it permits more
accurate gene expression analysis from patient to patient, it effectively halves the
sample population and reduces statistical power. Because healthy pancreatic
tissues are absent of nearly all mucins while PDAC cells express progressively
increasing amounts, I elected to use the malignant purity scores of all samples to
“normalize” the expression of mucins.
Using the mucin expression profiles, I explored a novel method for
subtyping PDAC tumors to better understand different routes of disease
progression, with the chief objective being better therapeutic approaches in the
clinic and ultimately improved survival of patients. The most accepted subtyping
strategies involve complicated and expensive sequencing of tumor samples to
either identify pathways impacted by genomic mutations
profiling of the whole tumor sample

178

22,

or transcriptomic

or microdissected samples

179.

I have

expanded on the well-established aberrant localization and overexpression of
mucins to define disease subtyping based on genes correlated with four groups of
co-expressed mucins. Pathway analysis of the correlated genes to each of the four
mucin clusters suggests that mucin expression might signal or be involved in
unique molecular fingerprints of PDAC tumors. I believe that the expression profile
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of mucin in PC1 promotes the immunological reaction, as indicated by the many
T-cell activation pathways. I have also shown that patients with a high expression
of these mucins survive longer than patients with low expression. However, I am
constrained by the incomplete data regarding lines of therapy given to the patients
in the TCGA dataset. Therefore, more studies are necessary to substantiate our
hypothesis.
Numerous studies have reported that malignant tumor cells demonstrate a
wide array of abnormal alternative splicing events in their expressed genes
197,

73, 77,

some of which may have novel or unregulated functions, prognostic

implications, or diagnostic potential with clinical implications. Therefore, I
employed a focused bioinformatics-based approach to investigate the expression
of mucin splice variants in PDAC tumor samples from TCGA patients. Expression
of four MUC1 transcripts revealed improved survival times, as did the expression
of full-length MUC13 and MUC20, while both MUC4 and the MUC15, full-length
MUC16, MUC21, and MUC22 SVs demonstrated decreased survival of PDAC
patients. The mechanisms by which these transcripts contribute to changes in
survival outcomes are not understood and require future study. Expression of
MUC1 is typical of many tissues and cell types, including gastrointestinal
epithelium, stromal cells, and immunocytes

198, 199.

Thus, the detection of these

transcripts may indicate the presence or activation of cells that impede aggressive
disease biology. MUC16, the largest described mucin, is not fully characterized,
and its contributions to biological and clinical aspects of PDAC are hypothesized
but not well documented. MUC4 is expressed in isolated tissues; however, its
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expression has been well established in PDAC cell lines and patient tumor
samples and absent in healthy pancreas

127, 138, 170, 200, 201.

Other groups have

demonstrated that expression of MUC13 is associated with a more aggressive
PDAC phenotype in cell line models 202, 203. However, our analysis from TCGA, as
well as within our validation samples, contradicts these findings. This disparate
observation may be explained by assessing the functional status of MUC13 during
tumorigenesis.
Notwithstanding these observations, no studies have evaluated the tumorspecific role and diagnostic potential of mucin SVs in PDAC. Our investigation of
mucin transcripts in PDAC transcriptomes demonstrated that splicing of exon six
from MUC4 presented with significantly decreased patient survival. This exon
codes for the N-terminal sequence of the NIDO domain. Despite an incomplete
understanding of the NIDO functionality, it has been linked to interactions between
the expressing cell and the surrounding extracellular matrix 129, 204, 205. Interruption
of the NIDO domain may permit loose adherence of PDAC tumor cells and
increase their mobility. However, I detected the expression of this SV concurrently
with MUC4WT, suggesting that the interaction of MUC4∆6 with MUC4WT may
result in reduced patient survival. If true, this further suggests that tumor cells
expressing this transcript possess an increased metastatic potential and elevate
disease aggressiveness.
Further, I found that high expression of MUC4∆6 is an adverse prognostic
marker and presented with significantly shortened survival in our validation PDAC
patients. In contrast, expression of MUC13WT was discovered to be a favorable
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prognostic finding and presented with more prolonged survival. Our ability to
observe statistically significant differences in survival from TCGA comes from its
large sample size. It is worth noting that the overwhelming majority of PDAC
patients are diagnosed with late-stage disease compared to the early-stage cases
represented in TCGA. The availability of patient samples for our validation studies
is significantly limited and may have contributed to the lack of statistical
significance in survival time when considering MUC13WT expression. Our
analysis is likely underpowered to detect differences in survival due to this
limitation. Nonetheless, I maintain that expressions of MUC4∆6 and MUC13WT
are unique to PDAC and should be considered when assessing the outcome
expectation of patients.
2.D Methods
2.D.1. Data Acquisition and Characterization
Our study was initialized by acquiring the normalized RNA-Seq data
(aligned to Genome Reference Consortium Human Build 38) of PC subjects
(PAAD) from TCGA along with the matched clinical details. Only confirmed PDAC
cases with complete clinical and cellularity data were retained for analysis (n=149
PDAC, n=3 normal adjacent). The expression of cell type-specific genes was
assessed in all cases for amylase 2A (acinar cells), CD45 (immune cells),
cytokeratin 19 (epithelial cells), leptin (adipose), and mesothelin (stromal cells).
Our secondary in silico cohort was comprised of the PACA-AU pancreatic cancer
downloaded from the International Cancer Genome Consortium (ICGC) and
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consisted of n=67 samples after filtering n=24 samples due to histological diseases
other than PDAC. The data were converted from the FPKM normalized values
reported in ICGC to TPM by the formula:

EQUATION 1: FPKM TO TPM CONVERSION

in order to make intergenic, cross-samples, and cross-dataset comparisons.
2.D.2. Realignment of RNA-Seq. Fragments and SV Calling
To account for updates to genome annotations, raw RNA-Seq reads were
acquired from the NIH Genomic Data Commons site. These reads were aligned to
the Ensembl 94 GRCh38 cDNA reference transcriptome [RRID:SCR_002344]
using Salmon 206 and the standard 31 k-mer index for high mapping accuracy.
2.D.3. Sample Cellularity Correction of Mucin Expression
The majority of mucins are expressed only by malignant epithelial cells of
PDAC. Therefore, the detected mucin mRNA transcript levels from each patient
required consideration of the proportion of tumor cells within the sample.
Fortuitously, each PDAC sample in the TCGA dataset reports the matched
cellularity score. This value was computed by the TCGA Consortium using the
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ABSOLUTE algorithm

142,

which assesses PDAC-specific transcripts and

comparative chromatin methylation states between PDAC and healthy pancreatic
cells. The result of the calculation is reported as a single number between 0 (all
normal cells) and 1 (all tumors cells). The normalized expression of all mucins was
divided by the respective cellularity scores. This permitted the inclusion of all
patients in a single population and comparable to each other rather than dividing
the cases into qualitative “high” versus “low” cellularity.
2.D.4. Mucin Splice Variant Validation in Patient Samples
In silico results were verified in a separate patient cohort (n=17) using
PDAC samples collected from pancreaticoduodenectomy procedures performed
at The University of Nebraska Medical Center. Total RNA was isolated from frozen
PDAC tissues by using the mirVana miRNA Isolation kit (Ambion). Complementary
DNA (cDNA) was synthesized using the iScript RT Supermix kit (Bio-Rad). Primers
were designed to amplify MUC4WT, MUC4∆6, both MUC4WT and MUC4Δ6
(MUC4-dual, for traditional PCR techniques), and MUC13WT. Primers designed
for all are reported in Table 2. Glucose phosphate isomerase (GPI) was used as
the reference gene

207

and selected primers are reported in Table 3. Cellularity

correlated genes were assessed in the TCGA PDAC dataset to determine a
plausible method to determine cellularity in the validation samples by PCR-based
techniques. Based on the analysis of cellularity-correlating genes, two positively
correlated genes, protein tyrosine kinase 6 (PTK6) and epithelial splicing
regulatory protein 2 (ESRP2), and one negatively correlated gene, melanoma-
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TABLE 2: MUCIN PRIMERS
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TABLE 3: HOUSEKEEPING GENE GPI PRIMERS
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associated antigen H1 (MAGEH1), expression were evaluated using the primers
in Table 4.
Gene expression was assessed using digital droplet PCR (Bio-Rad QX200
AutoDG system) and quantifying absolute transcript copies from approximately
12,000-20,000 droplet reads per target in each sample. Copy numbers were
calculated

within

QuantSoft

Analysis

Pro

(Bio-Rad

Laboratories,

RRID:SCR_008426) and back calculated to the copies per µL of input total RNA
isolated from patient tumor samples. Copy numbers of all genes were normalized
using respective GPI copies and reported as the number of transcripts per 1,000
copies of reference. Malignant cellularity of all samples was determined by dividing
the average normalized copies of PTK6 and ESRP2 by MAGEH1 (Equation 2).

EQUATION 2: CALCULATION FOR PDAC SAMPLE CELLULARITY BY PCR

Score ratios >1 were labeled as “High Cellularity” and all <1 were labeled “Low
Cellularity”. Expression of MUC13WT and MUC4∆6 were stratified about the
median c/cr and the overall survival.
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TABLE 4: CELLULARITY PRIMERS
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2.D.5. Statistical Analysis
Mann-Whitney-Wilcoxon (for 2 groups) or Kruskal-Wallis (for 3 groups)
tests were used to compare mucins between groups before and after cellularitycorrection. Post-hoc Dunn’s tests were calculated, followed by Bonferroni
corrections to adjust pairwise comparisons between groups. Significance levels
within sample types, cellularity, and cellularity correction state (corrected vs.
uncorrected) groups were corrected for false discovery errors in multiple
comparisons using the Benjamini-Hochberg method. Overall survival time and
cause of death were obtained and matched to respective patients from the
supplemental clinical data available from the National Institute of Health’s GDC
data portal or UNMC/Nebraska Medicine EHR. Survival time was measured in
days starting at diagnosis and ending on the patient’s death or end of the followup period. Kaplan-Meier method was used to estimate overall survival distributions
by mucin expression, categorized at the zero-excluding median as “high” or
“low/no” expression. The log-rank and Wilcoxon tests were used to compare
survival distributions. Principal component analysis by Spearman’s correlations
was calculated for all subjects using cellularity-corrected expression followed by
factor analysis using orthogonal rotation, with no significant differences between
unrotated and rotated eigenvectors. Based on the scores of each subjects’ PC,
they were stratified to the respective PC with top 25% (High), bottom 25% (Low),
and middle 50% (Moderate). Pathway analysis was conducted using Qiagen
Ingenuity Pathway Analysis software (RRID:SCR_008653) based on the foldchange of significantly correlated genes between high and low PC patients.
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Prediction of all patients to PCA-based subtypes was calculated by strongly
independent (naïve) Bayes analysis using 70% of the patients for training and 30%
for validation by receiver operating characteristic curves for the validation samples.
All statistical analyses conducted here were completed using JMP Pro statistical
suite or R.
2.D.6. Power Analysis
In our validation group, there were n=15 retained patient tumor samples;
and selecting an alpha=0.05, power=0.8, and a standard deviation=150, the
analysis is powered to detect a difference of 234.8.
2.D.7. Sex as a Biological Variable
The incidence of pancreatic cancer in males versus females is not
statistically different. Within TCGA PDAC samples, n=69 are female and n=81 are
male. Therefore, the sex of patients was not applicable to the design or conduct of
this study and was not considered.
2.D.8. Institutional Review Board
Data obtained from TCGA was approved following raw data acquisition
request submission and was received de-identified. All data were downloaded,
stored, and processed following the requirements established by the National
Cancer Institute’s Genomic Data Commons. Patient samples used in our study
were submitted to the UNMC tumor bank following Whipple resections and
consenting to have surplus tissue used for research purposes. Samples were
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procured by our lab under Aim 1 of IRB Protocol # 186-14-EP. Samples were
blinded by central processing upon intake to the tissue bank. This study was
computational and confirmatory in nature, and as such, the randomization of
subjects was not necessary.
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CHAPTER 3:
FUNCTIONAL ANALYSIS OF MUC4Δ6
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3.A Introduction
In summary of Chapter One, a bioinformatics analyses of TCGA revealed,
in part, that PDAC patients expressing the alternatively spliced mucin 4 (MUC4)
variant have significantly reduced overall survival. While aberrant expression of
many mucins is a well described phenomenon in PDAC

32, 33, 35, 161, 171,

the exact

involvement of mucins in disease pathobiology is complex and foundational
understanding is incomplete. Some studies investigating the role of MUC4 in
PDAC aggressiveness have suggested it may be involved in tumorigenesis
appearing early in the transformative process

35, 36, 131, 200, 201, 208,

tumor cell

migration 128, 130, 131, and therapeutic resistance 162, 163.
MUC4 is a large membrane-bound glycopeptide composed of 12
functional domains coded by 26 exons (Fig 3.1). 205 The exact role of each domain
in MUC4 is poorly understood but they have been suggested to contribute to matrix
and adjacent cell interactions127, 129-131, 189, 204 and intracellular signaling 170, 189, 201.
When considering the implication of altered domain coding through alternative
slicing, a few studies have demonstrated at least 22 different transcripts of MUC4.
137, 138, 140, 141

The variant identified in Chapter One of this work contains an in-

frame deletion of exon 6 (termed MUC4Δ6). Exon 6 is a 156 base pair sequence
coding for 52 amino acids at the N-terminus of the nidogen-1-like (NIDO) domain
downstream of the substantial tandem repeat region which lies upstream of the
adhesion-associated (AMOP) domain. I hypothesized that splicing of this exon
induces a steric hinderance between the extracellular matrix and the full NIDO and
AMOP domain, effectively reducing the binding potential or strength of MUC4 to
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Figure 3.1: Domain Moiety of MUC4

MUC4 protein is divided into 2 principal segments about its auto-cleavage site
(GDPH) generating a freed extracellular MUC4α, which enables MUC4 to interact
with surrounding stroma and adjacent cells, and membrane-tethered MUC4β,
which includes three suspected EGF-like domains and a von Willebrand domain
(vWD). MUC4α contains the hyper-glycosylated extensive tandem repeat domain,
a NIDO-like domain, and an AMOP domain. MUC4Δ6 demonstrates an in-frame
deletion of exon 6, which codes the 52 most N-terminal amino acids of the NIDO
domain adjacent to the tandem repeat.
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FIGURE 3.1: DOMAIN MOIETY OF MUC4
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the matrix. If true, the consequence of this modification would be a molecule with
reduced adhesion properties and an increase in migratory potential of the
expressing cell. To test this hypothesis, cell lines were established to enhance the
expression of MUC4Δ6 selectively.
3.B Results
The exploration of the functional role of MUC4Δ6 required the generation
of novel cell lines with enhanced expression of the MUC4 splice variant. Because
the MUC4Δ6 is expressed concurrently with MUC4WT, a cell line expressing the
sole MUC4 variant would fail to recapitulate the actual tumor environment more
accurately. Therefore, attempts were made to offset the ratio of MUC4WT to
MUC4Δ6 expression.
3.B.1. MUC4WT Knockdown
In line with the hypothesis that MUC4Δ6 functions in concert with
MUC4WT on the expressing cell, the first attempt to increase the splice variant
was conduct using transfection of shRNA targeting exon 6 of MUC4. In this way,
wild-type was expected to decrease and the consequential upregulation of MUC4
expression would increase the overall abundance of MUC4Δ6 in natively
expressing cells. Transfection of three shRNAs (see Methods and Materials) was
conducted in CD18/HPAF-II, T3M4, Capan-1, and COLO357 pancreatic cancer
cell lines. This knockdown failed in all cell lines except COLO357. Semiquantitative PCR using the dual MUC4 primers described in Methods and
Materials revealed shMUC4E6 #2 had the maximum reduction in MUC4WT
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expression with a drop of about 15% and an almost 25% increase in MUC4Δ6
expression (Fig 3.2A and 3.2B). However, these changes were not substantial
enough for consideration moving into functional studies. Further, the use of
puromycin antibiotic, necessary to stabilize and maintain enriched populations of
transfected cells, induced expression of MUC4 with vast amounts of wild-type
transcript (Fig 3.2C). As a result, this method of splice variant overexpression was
abandoned.
3.B.2. miniMUC4d6 Overexpression
Following the unacceptable modulation in MUC4Δ6 to MUC4WT
expression in my shRNA knockdown cell lines, I decided to attempt to establish an
overexpression system. I began with a miniature MUC4 construct containing 10%
of the tandem repeat domain sequence of wild-type MUC4 (miniMUC4)
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and

generated a miniMUC4Δ6 overexpressing construct (described in Methods and
Materials). The size of the MUC4 gene makes molecular alterations and sustained
fidelity of sequence quite challenging. Several PST-miniMUC4Δ6 transformed
bacterial colonies were confirmed by selective restriction digestions and gel
resolution, as well as DNA sequencing. CD18/HPAF-II, COLO357, and MiaPaCa2
cell lines were transfected and screened. By immunoblot detection, no transfected
cultures were confirmed positive for expression of the target gene using an antiMUC4 antibody or an anti-c-Myc-tag antibody, the epitope present on the Cterminus of vector coded transgene. RNA was isolated from transfected CD18/HPAF-II and COLO357 cell lines. Complementary DNA was synthesized from
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Figure 3.2: MUC4Δ6 Expression Enrichment by shRNA Knockdown of WildType

(A) Transfection of shRNA virus into COLO357 PDAC cells demonstrated limited
reduction in MUC4WT expression or increase in MUC4Δ6 expression. (B) Gel
resolution of dual MUC4 PCR amplicons. (C) Treatment of cells with puromycin
selection antibiotic enhanced overall expression of MUC4.

156

FIGURE 3.2: MUC4Δ6 EXPRESSION ENRICHMENT BY SHRNA
KNOCKDOWN OF WILD-TYPE
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isolated RNA and primers from the exon 6 flanking regions were used to amplify
the presence of PST-miniMUC4Δ6 vector sequence in transfected COLO357 cells.
Gel resolution of this confirmation PCR revealed that the cells contained and were
expressing the plasmid transgene with the appropriate size (Fig 3.3).
3.C Discussion
My results from Chapter 2 of this dissertation demonstrated that pancreatic
ductal adenocarcinoma patients expressing high alternative splice variant
MUC4Δ6 had significantly reduced median overall survival outcomes. These
observations were in accord by in silico analysis and by PCR in validation Whipple
samples. Previous studies have suggested that the NIDO domain of MUC4
enables the expressing cell to adhere tightly to neighboring cells and surrounding
stromal tissue. Additionally, some limited studies have postulated that NIDO further
enables MUC4 to interact with neural sheaths. This hypothesis is exceedingly
relevant because PDAC frequently demonstrates perineural invasion. Based on
these limited in vitro and computational studies, I hypothesized that MUC4Δ6, in
concert with MUC4WT, might reduce the overall binding of expressing cells to the
ECM and increase interaction with myelin cells to facilitate an aggressive nerve
fiber invasion. To begin to uncover the possible mechanisms behind these
observations, a model system of MUC4Δ6 was required. At first attempt, I
designed an shRNA targeting exon 6 of MUC4 and transfected several PDAC cell
lines. Though some relative enhancement of MUC4Δ6 expression was observed,
the overall modifications were subpar for their inclusion in experimental
investigations. The next concept attempted to overexpress MUC4Δ6 in PDAC cells
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Figure 3.3: MiniMUC4Δ6 Overexpression PCR in COLO357 Cells

COLO357 cells transfected with the new miniMUC4Δ6 overexpression vector were
assessed for expression of transgene by PCR. The non-transfected control cells
demonstrated the proper amplicon size matching miniMUC4 since the miniMUC4
amplicon contained the same sequence as full-length MUC4. All four miniMUC4Δ6
colony transfected cells demonstrated expression of the intended truncation
amplicon. To match the sequence of the insert in the miniMUC4 pST vector, it was
included as a control reaction.
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FIGURE 3.3: MINIMUC4Δ6 OVEREXPRESSION PCR IN COLO357 CELLS
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natively expressing MUC4WT. I modified a miniature MUC4 construct previously
designed by our laboratory that coded a 90% reduction in the tandem repeat
domain to exclude exon 6. Despite confirmation of proper molecular techniques
and results, as well as sequencing and PCR validations, I was never able to
establish the overexpression cell line. This failure was consistent over nine
independent attempted transformations and four reattempts at construct synthesis.
The major hurdle with the induction of a MUC4 gene is clearly its size. Fulllength MUC4 RNA is almost 16.8 kilobases coding a transmembrane core protein
that is around 230 kDa and as large as 900 kDa with its full glycocalyx. Molecular
cloning of full-length MUC4 is unlikely to be successful due to this prohibitive mass.
Modification and cellular manipulation of MUC4 is challenging to say the least.
Given that transfection of my miniMUC4Δ6 was unsuccessful, other potential
modalities of selective expression have been conceptualized. One very optimistic
idea to generate MUC4Δ6 expressing cell lines would involve the use of a
CRISPR/Cas system. The major drawback to this approach is gene edited cells
would exclusively express the splice variant without the ability to express wild-type
MUC4. Alternatively, a MUC4Δ6 cassette could plausibly be inserted into the
genome of cells. A potentially better approach would involve the use of small
interfering oligonucleotides to block the splice sites of exon 6 and promote the
selective splicing of the gene. This approach has merit and is well documented.
Studies to correct the mutation in the dystrophin protein in muscular dystrophy has
successfully induced the splicing exclusion of exon 51 in the mutant transcript
leading to a truncated but functional protein. Several molecules carrying the
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splicing directive oligonucleotide have moved into human clinical trials and the
results are exceedingly promising. Nonetheless, my bioinformatics and validation
results suggest MUC4Δ6 is an important aspect of PDAC pathobiology, and the
continued investigation into this splice variant seems obvious.
3.D Methods
3.D.1. Knockdown of MUC4WT
Three shRNA oligonucleotide pairs were designed to target exon 6 of fulllength MUC4 (Table 5) with Bgl-II and Hind-III restriction site sequences matching
the cloning restriction sites of the pSUPER.retro.puro (pSRP) short interfering RNA
expression vector (OligoEngine VEC-PRT-0002). Each oligonucleotide was
dissolved to a working concentration of 3 mg/mL in molecular grade water. To
anneal oligonucleotide pairs for insertion to the vector backbone, 1 µL of each was
combined in a 0.2 mL microcentrifuge tube along with 48 µL of annealing buffer
(100 mM NaCl, 50 mM HEPES pH 7.4). The reaction was annealed on a
thermocycler using the protocol: 90°C for 4 min, 70°C for 10 min, then step cooled
0.2°C per 30 sec to a final temperature of 10°C. The anneal insert was stored at
4°C until final plasmid preparation. The empty pSRP vector was linearized by
adding 1 µg to a 0.2 mL microcentrifuge tube with 5 µL of buffer 3.1, 1 µL of Bgl-II
restriction enzyme (New England BioLabs R0144S), and 1 µL of calf intestinal
alkaline phosphatase (CIP, New England BioLabs M0525) in a final reaction
volume of 50 µL. The reaction incubated at 37°C on a glass bead bath for 2 hours
before cleaning and reconcentration using a DNA cleanup kit. The entire eluate
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TABLE 5: SHRNA AGAINST MUC4WT
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was added to a 0.2 mL microcentrifuge tube with 5 µL of CutSmart buffer, 1 µL of
Hind-III High Fidelity restriction enzyme (New England BioLabs R0104S), and 1
µL of CIP. The reaction was incubated at 37°C on a glass bead bath for 1 hr then
gel resolved to validate proper linearization and isolate only dual cut vector free of
the stuffer sequence. The annealed oligonucleotides were digested with both
enzymes in the same manner described and gel purified. In a 3:1 w/w ratio, double
digested insert and linearized vector backbone were mixed in a 0.2 mL
microcentrifuge tube along with 2 µL ligation buffer and 1 µL T4 DNA ligase
enzyme (New England BioLabs M0202S) in a total 20 µL reaction. The ligation
reaction incubated at room temperature overnight. Competent E. coli bacteria were
transformed as described in section 3.B.3 and individual colonies were screened
for proper shRNA insertion. Colonies with confirmation by restriction digestion
were sequenced to obtain final validation of molecular reactions.
Positive colonies were expanded, and target plasmids were isolated by
midi-preparation. Phoenix-AMPHO cells (ATCC CRL-3213), which contain and
express the amphotropic envelope protein transgene, were cultured, and
expanded to 10 cm plastic cell culture dishes. Once cells were 50-75% confluent,
cultures were serum starved for 6 hours. In a 1 mL microcentrifuge tube, 500 µL
of serum-free media was added to 5 µg of plasmid, while in a second
microcentrifuge tube, 500 µL of media was carefully added to Polybrene
transfection reagent (1,5-Dimethyl-1,5-diazaundecamethylene polymethobromide,
Sigma Aldrich TR-1003G) in a final concentration of 10 µg/mL. The tubes were
flicked and briefly spun down to collect all solution. The plasmid mixture was
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carefully added to the Polybrene mixture dropwise. The mixture was flicked several
times, concentrated to the bottom of the tube, and incubated for 15 min.
Immediately before transfection of pSRP-shRNA plasmid, cultures were replaced
with 3 mL media. The plasmid-Polybrene mixture was added dropwise to cultures,
and plates were incubated at 37°C overnight before replacing transfection with 10
mL of free complete culture medium. Every 24 hr for 5 days, all media was
collected and replaced. Collected media was filtered through a 0.2 µm syringe filter
into a 15 mL tube containing 5 mL of sterile filtered polyethylene glycol 6000
solution and mixed to precipitate lentiviral particles. The tubes were incubated at
4°C until 24 hr after the 5th media harvest. All tubes were centrifuged at 1500 x g,
4°C for 30 min. The supernatant was aspirated, and the concentrated lentivirus
was combined from all five tubes, diluted to 500 µL with sterile PBS, and stored at
-80°C until infection of target cells.
3.D.2. Lentiviral Infection of Target PDAC Cells
Target PDAC cell lines were cultured until approximately 50% confluency
in a 10 cm plastic cell culture dish. The day of viral transfection, culture media was
replaced with 3 mL serum-free media and serum starved for 6 hr. Cultures were
inoculated with a viral titer from the previously prepared shRNA lentivirus and
incubated at 37°C for 12 hr before the addition of 3 mL complete culture media.
Transfected cell selection began 24 hr after lentiviral infection. Complete cell
culture media containing 5 µg puromycin per mL media was added to cells and
changed daily until all non-transfected control cells were dead. Cells cultures were
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dropped to 1 µg puromycin per mL media for maintenance. When stabilized cells
recovered and expanded, they were passaged and evaluated for target gene
knockdown.
3.D.3. Overexpression of miniMUC4
Cloning of full MUC4 into mammalian cells is challenging due to its
incredible size. Further, amplification of its tandem repeat domain is difficult due to
its repetitive sequence and the high G-C content. Our group previously engineered
a miniature construct of the MUC4 sequence that contains 10% of the tandem
repeat. This construct was cloned into the pSecTag2C plasmid vector. I used this
vector as the starting point for the engineering of our MUC4Δ6 transcript of interest
(Fig 3.4). Sequence analysis of the cloned miniMUC4 sequence identified two
single-cut restriction sites flanking the exon 6 sequence. PCR primers were
designed to anneal upstream of the BspE1 restriction sequence with a reverse
primer annealing at the base 5’ of the exon 6 sequence (5’ fragment). Immediately
downstream of exon 6, a forward primer annealing to the exon 7 sequence was
paired with a reverse primer annealing within the von Willebrand Factor (vWF)
domain downstream of the Blp1 restriction sequence (3’ fragment). The primers
(presented below in Table 6) adjacent to exon 6 contained the sequence coding
for the Sfi1 restriction site.
A 25 µL PCR was conducted using 1µL pSecTag2C miniMUC4 (~3µg
template), 67 mM Tris HCl; pH 8.3, 5 mM MgCl2 (Roche 10x PCR Buffer), 200µM
deoxynucleotide triphosphate (dNTP, Roche DNTP), 0.2 µM each of forward and
reverse primers, and 2 U of Q5 High Fidelity DNA polymerase (New England
166

Figure 3.4: pSecTag C-miniMUC4Δ6 Engineering

Beginning with an in-house engineered miniMUC4 (coding for 10% of the tandem
repeat domain) cloned into overexpression vector pSecTag C, fragments flanking
exon 6 were amplified by PCR introducing a novel Sfi-I restriction site used to
ligate the two fragments. The new Δ6 fragment and the parental pSecTagCminiMUC4 are sequentially double digested with BspE-I and Blp-I before ligation
of the modified sequence into the linearized partial miniMUC4 vector. The final
product was amplified by transformation of a competent bacterial host and
isolated by midi-preparation.
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FIGURE 3.4: PSECTAG C-MINIMUC4Δ6 ENGINEERING
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BioLabs M0491). Because the 5’ fragment was within the difficult to amplify tandem
repeat, 2% dimethyl sulfoxide (DMSO, Sigma Aldrich D2650) was included. The 3’
fragment was amplified using a PCR program of 95°C for 3 minutes (min), 45
cycles of (95°C for 30 seconds (sec), 60°C for 30 sec, 72°C for 1min), 72°C for 5
min. The 5’ fragment was amplified using a touchdown PCR program of 95°C for
3 min, 45 cycles of (95°C for 30 sec, 60°C for 30 sec [decreasing 0.2°C each cycle],
72°C for 2 min), 72°C for 5 min. Amplicons were resolved by electrophoresis on a
2% agarose gel containing ethidium bromide (Fig 3.5A). Bands were careful
extracted and purified amplicon fragments were isolated using a DNA gel
extraction kit (New England BioLabs Monarch T1020). The amplicons were further
amplified through a second round of PCR and purified using a PCR cleanup
protocol (New England BioLabs T1030). To prepare the two fragments for religation into the vector, the introduced Sfi1 restriction site was digested using 500
ng of amplicon, 5 µL of 10x CutSmart Buffer (New England BioLabs B7204), and
20 U of Sfi1 enzyme (New England BioLabs R0123) in a total reaction volume of
50 µL. The reaction was incubated in a glass bead bath at 50°C for 1 hour (hr)
before purification with a PCR cleanup protocol. The undigested fragments and
the ligated product were resolved and extracted from a 2% agarose/ethidium
bromide gel as previously described. To confirm proper annealing, the ligated
fragment was gel resolved (Fig 3.5B) and sequenced. The ligated amplicon was
further amplified by 40 cycles of PCR using the most distal primers and Q5 high
fidelity DNA polymerase and purified using a PCR cleanup. To ensure proper
orientation and retainment of the Sfi1 site, the ligated amplicon was digested again
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TABLE 6: PSECTAG C- MINIMUC4Δ6 PRIMERS
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with Sfi1 and gel resolved (Fig 3.5C). The original pSecTag2C miniMUC4 plasmid
was cut using the fragment restriction sites BspE1 (New England BioLabs R0540)
at the 5’ end and Blp1 (New England BioLabs R0585) at the 3’ end using the same
protocol described for Sfi1 but including 5 U of calf intestinal alkaline phosphatase
(CIP, New England BioLabs M0525) and using a PCR cleanup between each
enzyme. Concurrently, the ligated fragment was also dual digested in the same
manner and purified using PCR cleanup. Linearized vector and clonal fragment
were combined in a 1:3 volume ratio along with 2 µL of 10x T4 DNA Ligase buffer
and 400 U of T4 DNA Ligase (New England BioLabs M0202) in a total reaction
volume of 20 µL. The reaction was mixed and incubated at 25°C overnight.
3.D.4. Bacterial Transformation
After confirming ligation of exon 6 flanking fragments by gel
electrophoresis and DNA sequencing (UNMC Genomics Core), the plasmid was
used to transform high efficiency, endA1 deficient, competent E. coli (New England
BioLabs 10-beta C3019). A vial of 10-beta cells was thawed on ice for 20 min
before aliquoting 20 µL into a microcentrifuge tube. The entirety of the ligation
reaction was added to the tube with bacterial cells. The tube was carefully flicked
several times then incubated on ice for 30 min. The tube was then heat shocked
at exactly 42°C for exactly 30 sec then placed back on ice for 5 min. In a 10 cm
round culture dish, 10 mL of Luria-Bertani broth (LB) based agar (5 g peptone, 2.5
g filtered yeast extract, 2.5 g sodium chloride, 5 g agar in 500 mL and autoclaved)
containing ampicillin was solidified and cooled to room temperature. Following the
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final ice incubation, the bacterial cells were transferred and spread across the
surface. The plate was covered and incubated upside down at 37°C, 5% CO2
overnight. The next day, colonies were individually picked and expanded in 5 mL
LB broth overnight in a shaker incubator at 37°C and 200 rpm. Plasmids were
isolated from 1 mL culture using a plasmid mini prep kit (New England BioLabs
Monarch T1010). Plasmids from each colony were double digested with BspE1
and Blp1, as previously described, and resolved by electrophoresis (Fig 3.5D).
Plasmids producing the expected fragment size were sent for DNA sequencing to
confirm framing and proper sequencing.
3.D.5. Target Cell Transfection
Target mammalian cells were cultured in a 6-well plate from 5*106 until 9095% confluent. Cultures were serum starved for 6 hr prior to transfection. In two
microcentrifuge tubes, 100 µL of serum-free DMEM was added. In one tube, 10
µL of transfection reagent (TurboFect, Thermo Fisher R0531) was added while the
other tube received 1-5 µg of plasmid DNA. The tubes were gently flicked and
incubated for 5 min at room temperature. Then, the DNA mix was added into the
transfection reagent dropwise. The tube was gently flicked several times and
incubated at room temperature for 20 min. The media on the cells was aspirated
and replaced with 1 mL serum-free DMEM before adding the transfection reagentDNA mixture dropwise. The plate was gently swirled and incubated overnight at
37°C, 5% CO2. After 24 hr, 800 µL of DMEM with 10% bovine serum was added
to the well. The media was completely aspirated and replaced with 2 mL DMEM
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Figure 3.5: Restriction Digestion and Ligation of pST-miniMUC4Δ6

Each step of the modification of the miniMUC4 viral plasmid was visualized by
agarose gel electrophoresis and confirmed by sequencing. (A) PCR of the exon
6 flanking fragments confirmed a proper and specific 514 bp 5’ amplicon and 852
bp 3’ amplicon. (B) Ligation of the two fragments following Sfi-I restriction
digestion yielded a single amplicon of 1352 bp. (C) Validation of ligated clonal
fragment re-digested with Sfi-I resulted in two fragments matching the original 5’
and 3’ exon 6 flanking amplicons. (D) Following transformation of modified
pSecTagC miniMUC4Δ6 in competent bacteria, single colonies were picked from
ampicillin LB agar plates and expanded. Plasmids were isolated and double
restriction digested with BspE-I and Blp-I to confirm proper plasmid size.
Colonies were compared to double digest pSecTagC miniMUC4.
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Figure 3.5: Restriction Digestion and Ligation of pST-miniMUC4Δ6
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with 10% bovine serum after an additional 24 hr. After 48-72 hr, cells were exposed
to media containing Zeocin selection antibiotic. After confirming miniMUC4d6
expression by PCR and western blot using anti-MUC4 clone 8G7 antibody, cells
proceeded to in vitro experiments.
3.D.6. Western Blot Validation
Cells were grown in a 6-well plate until about 90% confluent. Wells were
washed twice with sterile PBS buffer and lysed with 100-150 µL of fresh, cold radioimmunoprecipitation assay buffer (RIPA, 50 mm Tris-HCl, pH 7.4; 0.25% Nadeoxycholate; 1 mm EDTA; 150 mm NaCl; 1% NP-40) containing with 5 mM
sodium orthovanadate, 5 mM sodium fluoride, and 1 mM phenylmethylsulphonyl
fluoride. Wells were scraped and added to microcentrifuge tubes, exposed to a 80°C freeze-thaw cycle, vortexed, and passed through an 18G hypodermic needle.
Lysates were centrifuged at 12,000 x g, 4°C for 20 min before supernatant was
isolated to a new microcentrifuge tube and stored at -20 °C until gel
electrophoresis. Lysates concentrations were standardized to a uniform 2 mg/mL,
after BCA assay quantification, diluting in complete RIPA buffer and adding 6x βmercaptoethanol protein dye. Prepared lysates were ran on 2% Tris-agarose gels
for 4 hr at 120 V. Resolved proteins were transferred to PVDF membranes by wet
passive diffusion overnight. Membranes were washed briefly with PBS and
blocked with 5% fat-free milk in PBS for 1 hr, then washed again with PBS.
Membranes were incubated with target (1:1000 anti-MUC4 8G7, 1:500 anti-MUC4
6E8, 1:2500 anti-β-actin, or 1:2000 anti-c-Myc 9E10) mouse anti-human
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antibodies. Membranes were wash three time with PBS-0.1% tween-20 (PBS-T)
buffer for 15 min each. Goat anti-mouse horseradish peroxidase secondary
antibody (1:5000, Thermo Fisher 31420) for 1 hr. Following secondary incubation,
membranes were again wash three times with PBS-T for 15 min each before 2 min
incubation with horseradish peroxidase chemiluminescence reagent (SuperSignal
West Dura, Thermo Fisher 34075). Luminescent membranes were exposed to
reactive film and developed for visualization.
3.D.7. PCR Validation
RNA isolated from transfected cells was converted to complementary DNA
synthesized using the iScript RT Supermix kit (Bio-Rad). A 25 µL PCR was
conducted using 1 µL cDNA, 67 mM Tris HCl; pH 8.3, 5 mM MgCl2 (Roche 10x
PCR Buffer), 200µM deoxynucleotide triphosphate (dNTP, Roche DNTP), 0.2 µM
each of forward and reverse primers, and 2 U of Q5 High Fidelity DNA polymerase
(New England BioLabs M0491). Amplicons were amplified using a PCR program
of 95°C for 3 minutes (min), 40 cycles of (95°C for 30 seconds (sec), 60°C for 30
sec, 72°C for 1min), 72°C for 5 min. Amplicons were resolved by electrophoresis
on a 2% agarose gel containing ethidium bromide and visualized with a gel UV
dock (Bio-Rad) or careful extracted and purified using a DNA gel extraction kit
(New England BioLabs Monarch T1020).
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4.A Introduction
With the majority of PDAC patients diagnosed with advanced disease and
the limitations of current PDAC therapies, the improvement of patient outcomes
depends on early diagnosis. Towards this goal, substantial progress in PDAC
diagnostic approaches and technologies is critical. Furthermore, the discovery of
disease-specific biomarkers is necessary for the development of early detection
assays. Currently, carbohydrate antigen-19-9 (CA19-9) is the only biomarker
approved for PC.26, 28-30, 209 Clinicians use CA19-9 to monitor therapeutic response
and detect disease progression. This marker, however, is not acceptable for
diagnostic applications. Therefore, novel markers for the early detection of PC are
needed to mitigate the rate of late-stage diagnoses and, likewise, PC mortality.
Suitable diagnostic biomarkers require that 1) the molecule is uniquely expressed
in the disease setting, 2) the marker is expressed early in the disease
establishment, 3) the marker is stably detectable, and 4) sample procurement from
patients is non-invasive and readily collectible, ideally from biofluids. Since PC
cases in TCGA are comprised of early-stage tumors, exploration of transcriptomic
data could identify early detectable biomarkers or prognostically relevant
transcripts. Aside from clinical staging and radiographic-based methods currently
in use, prognostic molecules may better distinguish those patients more likely to
benefit from surgical resection and spare those more likely to experience a rapid
post-surgical decline. Additionally, harnessing the power of next-generational
sequencing it is possible to screen large databases for potential novel biomarkers
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while also imparting a degree of disease parameter and patient selectivity to
improve the predictive power of results. Based on my preliminary assessment and
validation of mucin expression at the gene and isoform levels from PC patients in
TCGA, expression of MUC4∆6 contributed to poor survival outcomes in PC
patients. Expression of this MUC4 isoform has two implications, 1) the expression
of MUC4∆6 might identify patients with a more aggressive subtype of PC, and 2)
the expression of MUC4∆6 protein might influence the biology or pathology of PC.
Building off my previous results, I have synthesized photoswitchable
carboxyfluorescein

(FAM)-conjugated

DNA

oligonucleotides

(Fig

4.1)

complementary to the MUC4 exon 5-exon 7 junctional sequence using a thiolbound gold nanoparticle for optical quenching in the unbound state.210 When RNA
targets bind the nanoprobes, double-stranded nuclease recognizes perfect
hybridization and cleaves the DNA probe, stopping the fluorophore quenching, and
permitting its detection and quantification by a plate reader (Fig 4.2). Base
mismatches of even a single nucleotide generate bubbles in the double strand and
prevent enzymatic cleave ensuring that fluorophore detection is generated from
the target RNA alone (Fig 4.3). The RNA molecule is freed to cycle back and bind
another probe in a second order kinetic reaction. The number of probes is uniform
across reactions, but the number of matched RNA transcripts is patient specific.
The intensity of fluorescence detection is equivalent, but the rate to maximum
intensity reveals the concentration of target RNA.
My approach will demonstrate that the detection of circulating alternatively
spliced MUC4 RNAs is PC-specific and support their use as biomarkers. The novel
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Figure 4.1: Synthesis of RNA-Specific Gold NanoProbes

Probe synthesis begins with synthesis of 13 nm gold nanoseeds capped with
citrate (A) and grown to 40 nm (AuNPs) employing the Grabber synthesis
technique (B). After confirming integrity and size, AuNPs are PEGylated (C) and
concentrated (D). Next, AuNPs are conjugated to PEG linkers (E) and conjugated
to bait FAM-DNA oligonucleotides (F) before final washes and concentration (G).
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FIGURE 4.1: SYNTHESIS OF RNA-SPECIFIC GOLD NANOPROBES

181

Chapter IV: AuNP Detection Assay

Figure 4.2: Photoswitchable Fluorescent Probes are Detectable After
Enzymatic Cleavage

The detection of target RNA species via my novel gold nanoprobe assay relies on
activation of FAM following enzymatic Double-Stranded Nuclease (DSN) cleavage
of bait that have perfectly hybridized with target RNA. Imperfect hybridized pairs
induce a crinkle that inhibits DSN cleavage.
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FIGURE 4.2: PHOTOSWITCHABLE FLUORESCENT PROBES ARE
DETECTABLE AFTER ENZYMATIC CLEAVAGE
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Figure 4.3: Activation of FAM-Probe Requires Perfect Hybridization of Prey
RNA to Bait Sequence

FAM particles are quenched from electron sequestration by the gold nanoparticle.
Using an arctic shrimp enzyme DSN, which cleaves perfectly hybridized DNA
pairs, target RNA-bait DNA probes are acted on thereby freeing and activating the
FAM-DNA from the gold nanocore. Open, non-hybridized segments prevent the
enzymatic reaction of DSN, consequently imparting a tremendous degree of
specificity to this assay.
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FIGURE 4.3: ACTIVATION OF FAM-PROBE REQUIRES PERFECT
HYBRIDIZATION OF PREY RNA TO BAIT SEQUENCE
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assay presented in this chapter is further strengthened by the fact that it does not
require tissue, large sample volumes, complex processing, expensive and tedious
sequencing-based techniques, and is scalable for clinical utility.
4.B Results
4.B.1. AuNP Synthesis
Following the protocol detailed in the Methods section of this chapter, 13
nm gold nanoparticles (AuNP) seeds were assessed for size distribution by DLS
(Fig 4.4A). Given that DLS measures the particle including its hydroshell, the
diameters are slightly larger than labeled with the 13 nm seeds measuring an
average of 19.75 nm±5.7 and a polydispersity index (PDI) of 0.094 from more than
2.24*107 particles per read. The 40 nm particles (Fig 4.4B) measured an average
of 40.38 nm±11.5 and a PDI of 0.096 from more than 1.45*107 particles per read.
The PDI in both cases indicated a near perfect uniformity of size across analyzed
particles.
The concentrations of particles were calculated using a table of
nanoparticle physical properties based on particle size and the Beer-Lambert
formula (Equation 3) ; where A= the absorbance of light, ε= the molar absorption

EQUATION 3: BEER-LAMBERT EQUATION
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Figure 4.4: Verification of Gold Nanoseeds by DLS

Following the synthesis steps of both 13 nm (A) and 40 nm (B) gold nanoseeds,
particles are assessed by dynamic light scattering (DLS) to confirm uniformity of
size. Due to the presence of a hydroshell and its optical effect on DLS beams,
particle sizes are measured slightly above prescribed sizes. The greater the
degree of uniformity across nanoseeds within a single batch, the lower the
calculated polydispersity index (PDI) with anything less than 0.1 being acceptable.
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FIGURE 4.4: VERIFICATION OF GOLD NANOSEEDS BY DLS
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coefficient, b= the path length of light, and C= the concentration of particles. The
13 nm seeds had a max absorbance of 3.1 at 519 nm giving a concentration
around 3-4 nM while the 40 nm particles had a max absorbance of 0.55 at 528 nm
and a concentration around 8 nM (determination of concentration described in
Methods and Materials). The concentrations of all subsequent particle reactions
were calculated from the starting concentrations ascertained from the 13 nm and
40 nm UV spectroscopy facilitated calculations.
The AuNPs proceeded to PEGylation (AuNP-Peg) and linker (AuNPLinker) reactions before the final reaction to conjugate them to the DNA probes
(AuNP-Probe). Each batch of particles was assessed again by DLS and UV
spectroscopy. In each subsequent reaction, the particles increased their peak
absorbance (Fig 4.5A) and particle diameters (Fig 4.5B) with no significant change
in maximum wavelength or frequency rates, respectively. In order to assess the
true diameter and structure of the nanoparticles (NPs), a diluted sample was
mounted on grided silicon TEM wafer (Ted Pella, Inc) for transmission electron
microscopy (Fig 4.5C). Nanoparticle tracking analysis revealed that particles
spanned a near range around 44 nm. Particles were resolved on a 2% agarose
gel to visualize and confirm successful reaction and increases in native particle
size (Fig 4.5D).
4.B.2. AuNP-Probe Conjugation Quantification
Following AuNP-Probe synthesis, probes were degraded from particles
with DTT as described in Methods. Using a FAM standard curve (Fig 4.6), the
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Figure 4.5: Physical Characteristics of AuNPs and AuNP-Probes

(A) UV-visible spectrum. (B) The DLS spectrum of purified 13 nm nanoseeds; 40
nm AuNPs PEG-coated, Linker-bound and DNA conjugated AuNPs. (C) TEM
image of AuNP-Probe conjugated particles demonstrates uniform size and
dispersion of AuNPs. (D) Image of gel electrophoresis demonstrating successful
DNA-AuNP conjugation reaction. The reduced electrophoretic mobility of the
AuNP-Probe conjugation compare to the linker conjugated AuNPs reveals the
successful immobilization of DNA molecules on AuNPs surface.
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FIGURE 4.5: PHYSICAL CHARACTERISTICS OF AUNPROBES
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concentration of DNA probes was calculated by reading the total fluorescence and
cross referencing the dilution corrected concentration using the equation of the
standard curve to the final concentration of AuNP (Equation 4).

EQUATION 4: CALCULATION OF PROBES PER AUNP

The final calculations are presented using the table below. These calculated
concentrations were used to standardize the concentration of DNA-probes utilized
in the assay across targets and NP batches (Table 7).
4.B.3. Detection of MUC4 Wild-type vs MUC4Δ6 Synthetic Target
Synthetic RNA oligonucleotides (Integrated DNA Technologies) of MUC4Δ6 were
utilized to test the detection of varying concentrations of targets in this assay.
Detection of target transcripts by engineered AuNP-Probes follow second order
kinetics (Fig 4.7), thus the concentration of target RNA prey alters the slop of the
time-resolved fluorescence detection curve but not the peak intensity given enough
time for RNA recycling. The kinetic reaction plot of AuNProbe-MUC4Δ6
demonstrated a concentration-dependent slopes in FAM detection with the lower
limit of detectable concentration of target at 10 pM. RNA oligonucleotides matching
the exon 5-exon 6 and exon 6-exon 7 junctional sequences of MUC4 wild-type
(MUC4WT) were also designed (Integrated DNA Technologies) to evaluate the
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TABLE 7: AUNP CONCENTRATION CALCULATIONS

193

Chapter IV: AuNP Detection Assay

Figure 4.6: FAM Standard Curve Facilitates Calculation of DNA Probes per
AuNP

Using a FAM standard plot to generate a linear equation, the concentration of
FAM-DNA probes can be calculated. Since the concentration of AuNPs in solution
are known, the total number of FAM-DNA bait probes conjugated to each AuNP
can be determined in order to normalize the probe load in each reaction batch to
batch.
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FIGURE 4.6: FAM STANDARD CURVE FACILITATES CALCULATION OF
DNA PROBES PER AUNP
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TABLE 8: SYNTHETIC TARGET RNA SEQUENCES
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Figure 4.7: Limit of Detection of MUC4Δ6 RNA with AuNProbe-MUC4Δ6

The AuNP assay for MUC4Δ6 shows robust detection across a range of
concentrations. Complete detection of MUC4Δ6 target RNA is inferred by
plateauing of the curve. Low concentrations contribute to a low slope of the FAM
curve. The concentrations given in the legend are the concentrations of the input
sample, which comprise 10% of the entire reaction volume of 40 µL. Therefore,
the lower limit of detection given a perfect reaction environment is 10 pM.

197

Chapter IV: AuNP Detection Assay

FIGURE 4.7: LIMIT OF DETECTION OF MUC4Δ6 RNA WITH AUNPROBEMUC4Δ6
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specificity of the MUC4Δ6 AuNP probe under competitive binding contributed from
synthetic wild-type RNA species (Table 8). When compared to these MUC4WT
RNAs flanking the exon 6 sequence, detection of MUC4Δ6 RNA demonstrated a
high degree of specificity with no significant detection of nontarget RNA using the
MUC4Δ6 probe (Fig 4.8). The use of target sequence matched DNA prey instead
of RNA result in no difference in detected probe activation. Detection of FAM
activation was negligible when target RNAs are in the presence of wild-type RNA
indicating no general interference of binding potential imposed by the wild-type
sequences. Although it is more likely that this may have been attributed to lack of
non-specific enzymatic cleavage rather than differences in binding properties.
Potential variations in the interference effect were evaluated using varying
concentrations of combinations of target MUC4Δ6 RNA and nontarget MUC4WT
RNAs (Fig 4.9). When target MUC4Δ6 RNA were tested at either 100 nM or 1 nM
input (10 nM and 100 pM final, respectively), the slopes and maximum RFU
intensities were unaffected by the presence of one or both 100 nM MUC4WT (10
nM final) exon 5-6 junction or exon 6-7 junction RNA fragments. These results
suggested that the presence of both RNA species in biological fluids would be
unlikely to inhibit or interfere with target variant detection when using this assay.
4.B.4. Detection of KRAS Mutations
In similarly described methods, we designed probes to detect KRAS wildtype and the most commonly detected mutation in constitutively active oncogenic
KRASG12D. When these AuNP-Probes were evaluated for specificity and sensitivity
(Fig 4.10), the intended RNA target species was able to be detected, however, the
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Figure 4.8: AuNProbe-MUC4Δ6 Demonstrates A High Specificity to MUC4Δ6
Target

Specificity of the AuNP-Probe assay was evaluated using synthetic RNA and DNA
matching MUC4Δ6 and MUC4WT exon 6 flanking junctions. Positive detection was
observed only in reactions with the splice variant with minimal background from
negative control reactions.
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FIGURE 4.8: AUNPROBE-MUC4Δ6 DEMONSTRATES A HIGH SPECIFICITY
TO MUC4Δ6 TARGET
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Figure 4.9: MUC4WT RNA Does Not Interfere with MUC4Δ6 Detection

To evaluate if MUC4WT exon 6 flanking junctions could interfere with detection of
splice variant MUC4Δ6 within a single reaction well, MUC4Δ6 AuNP-Probe was
tested against combinations of single or double exon 6-containing wild-type RNA
fragments with two concentrations of splice variant. In all combinations, the
addition of one or both wild-type species had no interference with the reaction or
a reduction of the detected fluorescence.
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FIGURE 4.9: MUC4WT RNA DOES NOT INTERFERE WITH MUC4Δ6
DETECTION
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Figure 4.10: Validation of KRAS AuNProbe Specificity

AuNP-Probes were synthesized to target and detect constitutively active
oncogenic KRASG12D (A) and KRAS wild-type (B). Both probes were evaluated
against RNA of both variants. While both AuNP-Probes were able to detect their
intended targets across a range of concentrations from 1 µM to 1 nM, we observed
positive detection of nontarget species.
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FIGURE 4.10: VALIDATION OF KRAS AUNPROBE SPECIFICITY
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nontarget RNA also contributed to positive fluorescent readings. These results
were consistently observed across three separate syntheses of KRAS RNAs.
4.B.5. Sample Fragmentation
The large sizes of RNA were determined to cause steric hinderance to the
hybridization of probes to target RNA. Therefore, samples containing RNA were
fragmented using a salt-based reagent (described in Methods and Materials). To
evaluate the optimal fragmentation time, cell line RNA samples were subjected to
a series of increasing fragmentations intervals and assessed for RNA quality (Fig
4.11). At a reaction time of 15 min, RNA sizes were around 125-175 bp and
determined to be ideal for the application of this AuNP assay. No further significant
fragmentation was observed with additional reaction time, so a standard 20 min
reaction was elected to tighten the range of fragment sizes.
4.B.6. Detection in Murine Serum
Following the validation of my AuNP-probe assay with synthetic RNA
oligonucleotides, its utility with biofluid samples was evaluated. Serum was
collected from orthotopic mice implanted with CD18/HPAFII pancreatic cancer
cells. All samples were observed to produce positive reads for MUC4△6 RNA
transcripts except for one animal which produced signal not different from blank
and healthy human serum (Fig 4.12). Despite the low concentration of RNA in
circulation and the minimal sample used for this assay, a positive detection of
MUC4Δ6, which is natively expressed in CD18/HPAFII cells, supported the
expansion of this assay to include human PDAC patient samples.
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Figure 4.11: COLO457 RNA Fragmentation Validation

RNA from the COLO357 PDAC cell line were isolated and subjected to salt-based
fragmentation for 15 min, 2 hr, and overnight to evaluate the optimal fragmentation
reaction time.
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FIGURE 4.11: COLO357 RNA FRAGMENTATION VALIDATION
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Figure 4.12: Detection of MUC4Δ6 in Orthotopic Plasma

(A) Time resolved kinetic reads of fragmented orthotopic plasma demonstrated
positive detection of samples, although, the peak amplitudes were exceedingly low
compared to positive control reactions. (B) Blanked reads at maximum intensity
(occurred at 4 hr and 58 min), samples demonstrated minimal positive signal. (C)
Calculation of MUC4Δ6 RNA concentrations in samples revealed detectable
traces as low as 0.971 nM in the sample with the lowest signal.
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FIGURE 4.12: DETECTION OF MUC4Δ6 IN ORTHOTOPIC PLASMA
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4.B.7. Serum Preparation for Assay Detection
The addition of the fragmentation step was based on the assumption that
longer cell-free mRNA species might be inhibited from rapid hybridization due to
steric hinderance induced by large secondary structures. The low slope observed
from the orthotopic murine serum may have occurred due to few reasons, including
low concentration of MUC4Δ6 target RNA, lower reactivity of DSN, or lower than
calculated probes per AuNP. The most plausible explanation is that the
concentration of MUC4Δ6 RNA was artificially low. Fully exposed cell-free RNA in
circulation is likely degraded quickly and is mostly found inside exosomal bodies.
Therefore, a new procedural step was necessary to free and stabilize these RNA
species. Adapting a biofluid processing protocol from Wang et al.

211,

the same

orthotopic serum samples along with 3 control samples from saline injected mice
were preliminarily prepared using a proteinase K reaction to disrupt exosome
membranes and release the sequestered RNA before pelleting membrane and
protein components. This prepared sample was used in the AuNProbe assay as
isolated with an aliquot proceeding to fragmentation. Both sample preparations
were used for the detection of MUC4Δ6 RNA and compared to unprocessed serum
(Fig 4.13). This preparation failed to adequately detect the presence of target RNA.
Since the proteinase K preparation solution is mixed in a tris-boric acid buffer
containing ethylenediaminetetraacetic acid (EDTA), I hypothesized that the
magnesium cofactor for DSN was being quenched from the mix and inhibiting DSN
reactivity. The samples were prepared again, this time using EDTA-free buffer. As

211

Chapter IV: AuNP Detection Assay

Figure 4.13: Modification of Orthotopic Plasma Preparation Using
Proteinase K Pretreatment

To explore if the low signal-to-noise ratio of the AuNProbe assay was due to
sequestered RNA within circulating exosomes, orthotopic plasma samples were
subjected to proteinase K buffer pretreatment alone (Middle), pretreated with
proteinase K buffer then fragmented (Bottom), and compared to fragmentation
alone (Top). Only fragmentation treatment alone demonstrated a minor positive
detection while any proteinase K pretreatment resulted in inverse signal detection.
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FIGURE 4.13: MODIFICATION OF ORTHOTOPIC PLASMA PREPARATION
USING PROTEINASE K PRETREATMENT
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an experimental control, aliquots of orthotopic serum were prepared the initial way
and cleaned using a DNA/RNA cleanup protocol.
Following proteinase K preparation with the modified EDTA-free buffer, a
positive and amplified signal was detected in the orthotopic plasma samples (Fig
4.14). Concentrations from the previous proteinase K buffer preparations were
negative, and actually demonstrated inverse signal curves.
4.C Discussion
The specific and sensitive detection of disease biomarkers is a critical
checkpoint that prevents many diagnostic or prognostic assays from achieving
validation and progressing to clinical utility. In addition, these clinical assays can
typically accompany a high physical cost for patients paid in the contribution of
tissue samples collected through costly, invasive, and painful procedures. The
innovation of liquid biopsies promises to greatly reduce this burden as many
modern platforms can use a variety of biofluids, from urine, to blood or blood
fragments, to saliva. Still, early design and standardization approaches in assay
development require keen attention to sample processing, assay shelf-life, uniform
and replicable results, and minimalization of noise and false signal with increased
true detection. However, the fine tuning of true signal to noise becomes an intricate
dance between the assay sensitivity and the specificity of the intended detecton.
Here in this dissertation chapter, I have detailed the conceptualization of a novel
activatable gold nanoparticle assay targeting a pernicious RNA splice variant of
MUC4: MUC4Δ6, demonstrated earlier in this work to be indicative of an adverse
prognostic outcome in patients with pancreatic ductal adenocarcinoma. Our
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Figure 4.14: EDTA-Free Proteinase K Treatment of Orthotopic Plasma

(A) When orthotopic plasma was pre-processed with proteinase K buffer not
containing EDTA, assay reads amplified and demonstrated appropriate plateaus.
(B) Notably, the positive control demonstrated a higher maximum concentration
owing to the correction in prior EDTA-mediated chelation of magnesium. (C) The
calculated concentrations demonstrated about a 2-fold increase in detected
concentrations compared to the previous preparation buffer containing EDTA.
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FIGURE 4.14: EDTA-FREE PROTEINASE K TREATMENT OF ORTHOTOPIC
PLASMA
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innovative assay exhibited a high degree of specific detection which was unaltered
by the presence of wild-type MUC4 RNA. Additionally, my assay presented a very
strong sensitivity, detecting sample concentrations as low as 10 pM of target
MUC4Δ6 RNA. Through the validation of this assay using orthotopic and human
MUC4 transgenic animal plasma, it was revealed that additional procedures in
sample preparations were compulsory. My work demonstrated that large RNA
molecules possess intrinsic spatial properties which inhibit a robust hybridization
with the lure DNA probes conjugated to my gold nanocores. To address this issue,
a salt-based fragmentation process was conceived and implemented as a core
component of the pre-assay preparation. This process consistently reduced RNA
species to a near uniform size of around 200 basepair, in effect robustly increasing
their binding potential to the nanoprobes. My work also discovered that the
concentration of cell-free RNA in systemic circulation is high enough for adequate
detection using my assay. However, low detected signal in early experiments also
revealed that much of this RNA is locked inside extracellular bodies. Therefore, I
also devised a ‘first-step’ process of disrupting the membranes of these exosomal
bodies and neutralizing the membrane-integrated proteome using a custom
proteinase K buffer. In all, I was able to successful demonstrate that detection of
the MUC4Δ6 splice variant RNA is possible and was specific to PDAC-associated
plasma samples. Although, the number of healthy or negative control samples
employed in this work was limited. Advancing my MUC4Δ6-AuNProbe assay
further towards clinical use would require a robust and varied validation in human
samples.
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I also attempted to detect RNA of the most frequently expressed KRAS
mutant: KRASG12D. Specific DNA-probes complementary to this variant were
designed and tested. However, we were unable to meet the high threshold of
specific detection of mutant KRAS as the wild-type sequence also contributed
positive signal, albeit lower compared to KRASG12D. Exhaustive literature
investigation in the key enzyme enabling this assay to function, DSN, failed to yield
insight as to the probable cause of this false detection. Enzymatic function and
structural studies on DSN have been dominated on its interaction on DNA-DNA
hybrids, which have conclusively identified a 10-basepair binding site for DSN with
single strand cleavage between positions 6 and 4. Since our assay functions
through RNA-DNA hybridization, the binding properties of DSN are very likely
different than those exhibited in DNA-DNA reactions. Some preliminary and
unsubstantiated experiments suggested DSN requires a larger perfectly hybridized
segment hypothesized to be between 12 and 15 basepair. The lure sequence of
my DNA probes is 22 basepair, of which around 15-18 are believed to be
accessible to RNA for complementation. Detection of KRASG12D may benefit
changing the length of the DNA probe sequence.
In all, the work presented in this chapter has demonstrated a plausible and
promising foundation for a less-invasive diagnostic or prognostic assay detecting
alternative splice variants specific to disease states. While much work remains in
the optimization and validation of my AuNProbe assay, the optimistic results of
these experiments support the continued investigation of my platform. In addition,
I have demonstrated the possibilities of liquid biopsies which will undoubtedly
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continue to progress in the future, to the advantage of patients and their care
providers and healthcare teams.
4.D Methods and Materials
4.D.1. Synthesis of AuNPs
After ensuring that all glassware was sterilized and washed free of mineral
contaminates using Aqua Regia (1:3 nitric acid-hydrochloric acid). All water used
throughout the synthesis stages was triple-stage ultrafiltered. Grabar’s synthesis
212

of gold nanoseeds was initiated by bringing 250 mL of water and 2.5 mL 0.1 M

gold chloride trihydrate (HAuCl4, Sigma 52-0918) to reflux in a round bottom boiling
flask fitted with a condensation column flowing cold water under constant spinning
at ~900 rpm. Upon continuous reflux, 25 mL of 38.8 mM sodium citrate (Sigma
S2429) is quickly added to the flask. The solution undergoes a flash reaction
turning from pale red to clear then slowly darkens to black/dark blue. The solution
is boiled for an additional 10 min then cooled to room temperature. A small aliquot
is passed through a 0.45 µm PTFE filter (Acrodisc) and loaded into a 1 cm cuvette
for UV spectroscopy (Molecular Devices SpectraMax) and dynamic light scattering
(DLS, Malvern Zetasizer Nano ZS) analyses. Seeds that measure ~12-13 nm and
have a polydispersity index (PDI) <0.2 are approved to continue through synthesis.
To grow gold nanoparticles (AuNPs), 250 mL of water is added to a glass
round bottom boiling flask spinning at ~600 rpm along with 1.5 mL filtered gold
nanoseeds. To reduce the gold salt, 1 mL of 40 mM hydroxylamine (Sigma
159417) is added to the flask. Dropwise (approximately 100 mL/hr), 20 mL of 1.25
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mM HAuCl4 solution is added to the flask using an infusion pump (Fisher Scientific
78-01001). After the last HAuCl4 drop has been dispensed, the solution spins for
an additional 1.5 hr before 7 mL of 38.8 mM sodium citrate is added to cap the
newly grown ~40 nm AuNPs. These AuNPs are concentrated by ultracentrifugation
(Thermo Fisher Sorvall RC 50 Plus) at 10,000 rpm, 4°C for 15 min. The
supernatant is carefully removed and AuNPs isolated in a total volume ~2 mL.
The AuNPs are then proceed to PEGylation. In a 5 mL amber glass vial,
870 µL of water is combined with 120 µL of 5 mM SH-PEG-600-NH2 (Advanced
BioChemicals, Lawrenceville, GA), 680 µL of 5 mM SH-PEG-600-COOH
(Advanced BioChemicals, Lawrenceville, GA), and the concentrated AuNPs (~6-7
nM). A color change reaction from black/blue to red is observed by adding 330 µL
of 300 mM sodium bicarbonate (NaHCO3, Sigma S5761) solution to the vial before
spinning with a magnetic bar for 72 hrs.
Following 72 hr, the reaction solution is added to a 50 kd filter concentrator
(Millipore Amicon Ultra-4 50 kd) column pre-flushed with 50 mM NaHCO3. The
filter column is spun at 3000 rpm and 15°C for 5 min (Thermo Fisher Sorvall
Legend X1R). A four-step washing procedure follows the initial concentration step
with each step spun at 3500 rpm, 15°C for 10 min each. The washing solutions
proceed with:
1) 1 mL of 1:1 H2O-50 mM NaHCO3
2) 1 mL 4:1 50 mM NaHCO3-200 proof Ethanol (pure EtOH)
3) Repeat wash 2
4) 1 mL 50 mM NaHCO3
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Following the final wash, the AuNPs are collected in approximately 300
µL and loaded onto a sephadex G-25 purification column (illustra NAP-10) that
was pre-flushed with 50 mM NaHCO3. To run AuNPs through the purification
column, 50 mM NaHCO3 is loaded above the AuNPs in 500 µL boluses. The
purified AuNPs are collected in ~500 µL via gravity drip.
Washed and purified AuNPs are conjugated with PEGylated SMCC
crosslinker molecules (Thermo Fisher 22103) to prepare for functionalization. In a
1.7 mL microcentrifuge tube, 80 µL water is added to the purified AuNPs, 120 µL
of 200 mM phosphate buffer pH 8.5 (Sigma S2429), and 100 µL of 75 mM
SM(PEG)2 linker in dimethylformamide (Sigma 227056) solution under nitrogen
gas. The reaction is incubated in a thermoshaker (Eppendorf ThermoMixer C) at
1500 rpm, 4°C for 4 hr. Following the reaction, the AuNP-linker (AuNP-L) solution
is loaded into a 50 kd filter concentrator column with 500 µL of 200 mM phosphate
buffer pH 8.5 and spun at 3500 rpm, 4°C for 7 min. To remove unreacted AuNPs
and linker molecules, a series of washes proceeds as follows:
1) 1 mL of 4:1 200 mM phosphate buffer pH 8.5- pure EtOH
2) Repeat wash 1
3) 1 mL cold H2O
4) Repeat wash 3
The AuNP-L are collected in ~200 µL and functionalized by conjugation with DNA
oligonucleotides complementary to RNA targets.
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4.D.2. Functionalization of NPs
Our RNA targets of interest were selected from the bioinformatics analysis
from Chapter 1. I elected to target MUC4Δ6, which correlated with increased
mortality in TCGA patients. Using a 21-basepair sequence that spanned the exon
5-exon 7 junction site of this transcript, I designed probes with a 5’- 6carboxyfluorescein

(FAM)

and

3’-Thiol

modifications

(Integrated

DNA

Technologies, Coralville, Iowa). Based on the frequency and increased
aggressiveness of PDAC tumors with activating KRAS mutations, I also designed
probes to target KRAS wild-type and the most common KRASG12D mutation. The
probe sequences designed from bioinformatics in Chapter One and genomic
mutation analysis are presented in Table 9.
To prepare the probes for the conjugation reaction, 10 µL of 50 mM tris(2carboxyethyl)phosphine (TCEP, Sigma 75259) is combined with 10 µL of 400 µM
of reconstitute probe to reduce the thiol bond. The reaction is incubated at room
temperature in the dark for 1 hr before washing and purification of reduced probe
molecules through a NAP-5 sephadex column. Reactive probes are collected in
~200 µL.
In a microcentrifuge tube, 200 µL of 8-10 nM AuNP-L are combined with 80
µL water, 20 µL of 200 mM phosphate buffer pH 7.2, 20 µL of 4 M sodium chloride
solution, and the 200 µL purified 200 µM TCEP-treated probe. The final reaction is
incubated in a thermoshaker at 800 rpm and 4°C overnight followed by an increase
to 1000 rpm for 1 hr to allow probes to bond with the distal end of linker molecules.
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TABLE 9: AUNP PROBE SEQUENCES
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The nanoprobes (NPs) are pelleted by centrifugation at 10,000 rpm and 4°C for 10
min. The supernatant containing all unreacted probes is decanted and pelleted
NPs are resuspended in 500 µL of cold 50 mM NaHCO3 before filtration through a
50 kd concentrator at 3500 rpm and 4°C for 5 min. Washed and concentrated NPs
are washed and purified further by three additional washes of 1 mL 50 mM
NaHCO3. The final purified NPs are collected and resuspended in a total volume
of 500 µL 50 mM NaHCO3 and stored in a dark box at 4°C until use.
4.D.3. Particle Quality Assessment and Quantification
Each batch of NPs contains a similar concentration of AuNPs (3-5 nM),
however, the number of probes per AuNP is variable. To begin this calculation, the
NP size and concentration are ascertained by comparing the peak wavelength
absorption from UV-vis spectroscopy to known values of nanoparticle diameters,
concentrations, molar extinction coefficients, and molar concentration. The
uniformity of particle size is assessed by DLS analysis. Particle structure is
assessed by transmission electron microscopy imaging. The concentration of
probes per volume of NPs must be quantified in addition to several particle quality
checks. To quantify the concentration of probes, a 20 µL sample of NPs are mixed
1:4 with 1M dithiothreitol (DTT, Thermo Fisher R0861) in 0.2 M phosphate buffer
pH 7.8. The NP-DTT sample is agitated at 50°C overnight to completely reduce
probes then sonicated for 5 min and centrifuged (10,000 rpm, 10 min). The next
day, 20 µL of sample is combined with 180 µL of 50 mM NaHCO3 and loaded in a
96-well plate. A single timepoint, total fluorescence read is captured for triplicates.
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The fluorescence of NPs is compared to a 6-FAM calibration curve to yield the
diluted concentration of probes. This concentration is corrected for dilution (by a
factor of 200). Using the molar ratio of unknown NP-Probe to previously measured
AuNP concentration yields the number of probes per AuNP in solution.
4.D.4. Assay Reaction Mixture
For each reaction, 4 µL of 10x DSN reaction buffer (500 mM Tris-HCl pH
8, 10 mM DTT) is combined with 4 µL 500 mM NaCl, 4 µL 50 mM MgCl2, 4 U
RNase inhibitor (SUPERace-In, Invitrogen AM2694), and a final concentration ~10
nM of DNA-probes on NPs are combined and brought to a total reaction mixture
volume of 33 µL with water. The reaction mix is added to a 384-well black plate
(Corning 3571) with 4 µL of sample. The wells are mixed and spun down before 3
U of DSN per µL of reaction (ArcticZymes 70600-202) in a total of 3 µL water is
added to each reaction well. The wells are then topped with 10 µL silicone oil
(Sigma 146153) to suppress evaporation during the reading phase.
4.D.5. Assay Reading
Plates are analyzed in a multimode plate reader (BioTek Synergy Neo2)
incubating at 42°C without agitation. Using top optics, fluorescence endpoints are
captured for each well at a read height of 4.25 mm and gain of 100. The xenon
lamp energy is set to low with excitation wavelength at 484 nm (bandwidth 20) and
the emission wavelength detected at 530 nm (bandwidth 25). Readings are taken
every 60 seconds over the course of 5 hr for a total of 301 readings.
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4.D.6. Sample Fragmentation
Because the size of sample RNA imposes a steric hinderance to probe
binding, a salt-based nucleic acid fragmentation (Invitrogen AM8740) step was
included. For this reaction, 9 µL of sample serum and 9 µL water are mixed with 2
µL of fragmentation reagent and incubated at 70°C for 20 min. After the reaction
time, 2 µL of reaction stop reagent are added to each tube and mixed thoroughly.
Samples proceed to assay detection immediately after the fragmentation reaction.
4.D.7. Proteinase K Preparation of Serum Samples
Proteinase K solution was prepared by combining 2x tris-boric acid-EDTA
buffer with 1.2 M NaCl, 0.4% sodium dodecyl sulfate (SDS), and 25% (w/v)
proteinase K (Sigma 1245680500). Serum samples and proteinase K solution
were combined in a 1:1 ratio, incubated at 90°C for 5 min, immediately moved to
ice for 2 min, and centrifuged at 13,000 x g for 5 min until pellet formed. The RNAcontaining supernatant was isolated and used for assay detection or fragmented.
After this preparation failed to yield acceptable results, a second preparation was
generated exactly as the first except EDTA was eliminated to prevent the chelation
of DSN cofactor magnesium from the reaction.
4.D.8. Patient Plasma Samples
Patient plasma samples were isolated and processed from whole blood
collected at Nebraska Medicine and stored at -80°C. The collection included
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samples from PDAC patients at multiple stages of disease, as well as patients
diagnosed with pancreatitis and healthy donors.
4.D.9. Institutional Review Board
Patient samples used in our study were submitted to the UNMC Tissue
Bank following proper informed consent procedures to have surplus tissues used
for research purposes. Samples were procured by our lab under Aim 1 of IRB
Protocol # 186-14-EP. Samples were blinded by central processing upon intake to
the tissue bank.
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CHAPTER 5:
CONCLUSION
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The complex establishment of the pancreas from the foregut epithelium in
embryos is a highly regulated, multi-layered, and precisely synchronized process.
While not all signaling pathways and molecular crosstalk events are fully
described, the complexity and uniqueness of recycled molecules in novel functions
regarding pancreatic development demands admiration and respect. From
discordant beginnings, as sole foregut epithelium absent a mesenchymal layer,
the pancreas is arguably one of the most pivotal evolutionary developments
permitting advanced life to arise and flourish. However, loss of homeostasis within
the pancreas contributes to diseases that are life altering at best and life-ending at
painful worst. Whether loss of β-cells before or after lost insulin effects in diabetes,
or necrosis and fibrosis due to runaway activation of digestive enzymes as seen in
pancreatitis, or the myriad alterations and loss or gain of functions of signaling
molecules in PDAC, the balance of regulation in the pancreas is poised on a fine
point. Any shift in this balance point results in catastrophic consequences and
clinical interventions are often unable to reinstate normal functions easily. Diabetes
has been one exception in which research and the advent of recombinant insulin
were miraculously able to suspend what had once been a death sentence
diagnosis. As more work is complete and we uncover more details about the
intricate, submicroscopic workings of pancreatic cells, we will undoubtedly expose
more questions than conclusions. However, given the changes in cell signals and
tissue architecture, one must wonder if some of those answers lie in returning to
the beginning, to the remarkable regulation of pancreatic development.
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The expression and function of several mucins have been investigated
within the context of PDAC; however, the scope of these studies is generally
limited to single mucin. A complete exploration of mucin expression in PDAC has
not been conducted prior to this work. The establishment of cancer transcriptome
databases has increased our ability to assess the potential role of previously
unrecognized genes and their variants in specific malignancies. Other studies have
reported employing widely used databases to conclude that the expression of
MUC4, especially when combined with MUC16 and MUC20, was significantly
associated with worse survival outcomes in PC patients 194. Until present, no study
has addressed the need for cellularity-based correction of the RNA-Seq dataset
due to the variable and often a low number of malignant cells present in PDAC
tissues

195, 196.

This seemingly innocuous oversight obscures the real effects of

genes expressed by cancer cells within PDAC tumors. Furthermore, albeit more
detrimental, is the indiscriminate use of databases that fail to control for or stratify
reported cases adequately. Here I ensured that PDAC samples were correctly
vetted before selection. Several groups analyze all PDAC samples in TCGA and
inaccurately include samples that were annotated as less than 1% cellularity,
neuroendocrine, or primaries of unknown origin, among others. The difference in
survival outcome in pancreatic cancer is intrinsic to the type, with PDAC have
significantly worse survival. Indiscriminate stratification TCGA samples by mucin
expression essentially separates neuroendocrine tumors from PDAC, which the
former having substantially better survival.
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My work has demonstrated that the proportion of malignant cells present in
transcriptome sequenced tumor samples has significant impacts on addressing
biostatistical questions. PDAC is well known to contain only a minor malignant
compartment with the bulk of the tumor comprised of stromal along with abundant
acellular matrix proteins

25, 213, 214.

This concern was addressed by the TCGA

Consortium, which used a computational algorithm (ABSOLUTE Scoring) to
quantitatively determine the cancer cell population of tumor samples based on
gene expression and chromatin methylation states

142.

Based on these scores,

they assigned qualitative cellularity labels (high or low cellularity) to each sample.
This method, while resourceful, poses a statistical dilemma. While it permits more
accurate gene expression analysis from patient to patient, it effectively halves the
sample population and reduces statistical power. Because healthy pancreatic
tissues are absent of nearly all mucins while PDAC cells express progressive
amounts, I elected to use the malignant purity scores of all samples to “normalize”
the expression of mucins. In this way, I was able to maintain the full pool of TCGA
samples in my statistical analysis and increase the reliability of the results.
In the validation RNA-Seq dataset, however, and like other large cancer
databases, the absence of genomic sequencing data prevented the calculation of
the ABSOLUTE purity score and, likewise, disallowed malignant cellularity
correction or stratification. Consequently, the epithelial samples in this dataset
must be comprised of a wide range of malignant cell proportions. Therefore, the
expression profiles in this dataset were compared to the TCGA uncorrected mucin
expression values; and the epithelial expression was noticeably similar to that
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observed in the pooled TCGA uncorrected expression. The observation of
epithelial-associated mucin expression in the validation stromal samples was
unexpected and could possibly be explained by the communication of mucin RNA
out of the tumor and into the surrounding ECM by extracellular vesicles or
exosomes.
When I compared the correction-based clustering of mucins in the epithelial
samples of the validation dataset to the pooled uncorrected TCGA mucin clusters,
there was some observed discordance despite showing similar log-transformed
values. In exploring this disharmony, I observed substantial differences in the
mapped sequencing depth between the two datasets, with the TCGA samples
having between 60M-150M reads while the validation dataset had around 8M-33M
reads. This difference may explain why certain mucin expression anticipated to be
high, like MUC4, was observed lower than some higher observed mucins, like
MUC16, which were expected to be low.
Using the mucin expression profile, I attempted the PDAC subtyping to
better understand different routes of disease progression with the chief objective
being better therapeutic approaches in the clinic and ultimately improved the
survival of patients. Several groups have published works that have significantly
advanced the biological understanding of PDAC subtypes. The most accepted
subtyping strategies involve complicated and expensive sequencing of tumor
samples to either identify pathways impacted by genomic mutations
transcriptomic profiling of the whole tumor sample
179.

178

22,

or

or microdissected samples

I have expanded on the well-established aberrant and overexpression of
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mucins within PDAC tumors. While it has been documented that specific mucins
are expressed at crucial points during PDAC progression, my study was the first
to attempt to define disease subtyping based on genes correlated with four groups
of co-expressed mucins. Pathway analysis of the correlated genes to each of the
four mucin clusters suggests that mucin expression might signal or be involved in
unique molecular fingerprints of PDAC tumors. I believe that the expression profile
of mucin in PC1 promotes the immunological reaction, as indicated by the many
T-cell activation pathways. I have also shown that patients with a high expression
of these mucins survive longer than patients with low expression. While the other
three types do not significantly impact survival outcomes in patients, they may
identify subtypes with which specific treatment options could be more prudent.
However, I am constrained by the incomplete data regarding lines of therapy given
to the patients in the TCGA dataset. Therefore, more studies are necessary to
substantiate my hypothesis.
Numerous studies have reported that malignant tumor cells demonstrate a
wide array of abnormal alternative splicing events in their expressed genes
77, 197, 215,

73, 74,

some of which may have novel or unregulated functions, prognostic

implications, or diagnostic potential with a clinical impact. Therefore, I employed a
focused bioinformatics-based approach to investigate the expression of mucin
splice variants in PDAC tumor samples from TCGA patients. Assessing all known
mucin transcript variants, I concluded that 12 total mucin SVs, four MUC1, two
MUC4, and a single SV each of MUC13, MUC15, MUC16, MUC20, MUC21, and
MUC22, have significant associations with survival outcome in patients.
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Expression of all MUC1 transcripts revealed improved survival times as did the
expression of MUC13 and MUC20, while both MUC4 and the MUC15, MUC16,
MUC21, and MUC22 SVs demonstrated decreased survival of PDAC patients. The
mechanisms by which these transcripts contribute to changes in survival outcomes
are not understood and require future study. Expression of MUC1 is typical of
many tissues and cell types, including gastrointestinal epithelium, stromal cells,
and immunocytes

198, 199, 216, 217.

Thus, the detection of these transcripts may

indicate the presence or activation of cells that impede aggressive disease biology.
MUC16, the largest described mucin, is not fully characterized, and its
contributions to biological and clinical aspects of PDAC are hypothesized but not
well documented. MUC4 is expressed in isolated tissues; however, its expression
has been well established in PDAC cell lines and patient tumor samples and
absent in healthy pancreas 127, 138, 151, 170, 200, 201. Other groups have demonstrated
that expression of MUC13 is associated with a more aggressive PDAC phenotype
in cell line models 202, 203. However, my analysis from TCGA, as well as within my
validation samples, contradicts these findings. This disparate observation may be
explained by assessing the functional status of MUC13 during tumorigenesis.
Notwithstanding these observations, no studies have evaluated the tumorspecific role and diagnostic potential of mucin SVs in PDAC. My investigation of
mucin transcripts in PDAC transcriptomes demonstrated that splicing of exon six
from MUC4 presented with significantly decreased patient survival. This exon
codes for the n-terminal sequence of the NIDO domain. Despite an incomplete
understanding of the NIDO functionality, it has been linked to interactions between
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the expressing cell and the surrounding extracellular matrix

129, 139, 204, 205.

Interruption of the NIDO domain may permit loose adherence of PDAC tumor cells
and increase their mobility. However, I detected the expression of this SV
concurrent with MUC4WT, suggesting that the interaction of MUC4∆6 with
MUC4WT may result in reduced patient survival. If true, this further suggests that
tumor cells expressing this transcript possess an increased metastatic potential
and elevate disease aggressiveness.
I validated the expression of MUC4∆6 and MUC13WT in a separate patient
tumor cohort, observing that expression of both genes is higher in samples
containing higher malignant cells. Further, I found that high expression of MUC4∆6
is an adverse prognostic marker and presented with significantly shortened
survival in my validation PDAC patients. In contrast, expression of MUC13WT was
discovered to be a favorable prognostic finding and presented with more prolonged
survival. My ability to observe statistically significant differences in survival from
TCGA comes from its large sample size. It is worth noting that the overwhelming
majority of PDAC patients are diagnosed at late-stage disease 144, 218 compared to
the early-stage cases represented in TCGA. Although, the availability of patient
samples for my validation studies is significantly limited and may have contributed
to the lack of statistical significance in survival time when considering MUC13WT
expression. The analysis is likely underpowered to detect differences in survival
due to this limitation. Nonetheless, I maintain that expression of MUC4∆6 and
MUC13WT are unique to PDAC and should be considered when assessing the
outcome expectation of patients.
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These bioinformatics results and experimental validations supported the
further investigation of mucin splice variants and their roles in PDAC pathology.
Because MUC4Δ6 was consistently observed to coincide with a worse prognosis
and reduced overall survival, it was selected for additional research. Due to the
dismal median survival of patients diagnosed with PDAC, the discovery of novel
biomarkers might prove exceptionally beneficial clinically. Therefore, a novel gold
nanoparticle-based assay was conceived and developed to detect this variant in
patient biofluids, a method most likely to have a significant clinical advantage due
to the minimally invasive nature of sample collection. The positive results achieved
from this assay might prove impactful enough to support its expansion and
redesign for in-clinic screening of suspected PDAC patients or to provide a clearer
perspective of disease conditions to the medical provider and patient.
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Based on the results obtained from the MUC4Δ6 in vitro experiments and
the limited literature regarding the putative functions of the NIDO domain, future
studies of this splice variant will investigate the possibility of MUC4Δ6 contributing
to infiltration of specific tissues. A small collection of studies has suggested that
the role of the NIDO domain is to facilitate interaction with the surrounding matrix.
Loss of exon 6 in MUC4 brings the tandem repeat and remaining portion of the
NIDO domain closer in proximity and may cause the large glycosyl branches to
obstruct interaction between NIDO and the ECM. Biophysical studies on domains
that contribute to MUC4 speculate that the AMOP domain may have an affinity for
interacting with Schwann cells of the neuronal or myelin sheath. Therefore, future
studies will investigate the potential enhancement that the inhibition of NIDO-ECM
interactions and consequential enhanced mobility of its expressing cell has on
AMOP-neuronal interactions and its role in PDAC neuronal invasion. Towards
accomplishing these future functional studies, approaches to enriching the
expression of MUC4Δ6 in cells must be completed aside from those attempted and
presented in Chapter 3.
The negative results of KRASG12D detection with the AuNP assay described
in Chapter Three deserve future consideration. Investigating the potential causes
of nonspecific KRASWT and KRASG12D detection, it was uncovered that the
enzyme enabling this assay to function, Double-Stranded Nuclease (DSN), has
been poorly investigated in terms of its reactivity against RNA-DNA hybrids and
previous work has predominately focused on DNA-DNA activity. DSN is extracted
from the hepatopancreas of two arctic marine crustaceans, Paralithodes
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camtschaticus (Kamchatka or Red King crabs) and Pandalus borealis (Great
Northern Prawn). Studies involving the properties and applications of DSN are
nonconverging, dividing important aspects of the enzyme between both species.
In experiments involving DSN digestion of DNA-DNA pairs, both enzymes have
been found to have a binding site requiring 10 perfectly pair bases, where cleavage
occurs between basepair 6 and 4. Further, DSN has been shown to preferentially
cleave DNA in a DNA-RNA hybrid. However, the length of perfect hybridization is
controversial, falling somewhere between 12-15 basepair. DNA-Probes are
designed with 20 bases to yield spacing away from the gold core to facilitate RNAProbe hybridization and DSN interaction. Thus, a single base mismatch in the
KRAS assay may still allow DSN to recognize full pairing on either side of the SNP
and cleave the probe from its gold quencher. Future studies should investigate the
function of DSN across multiple sizes of RNA-DNA hybrids to better consider the
role hybrid length has on enzymatic recognition, binding, and cleavage. A more
complete understanding of these aspects will enable adaptations of the
aforementioned assay for other future experimental approaches.
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